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Rosiglitazone (rosi) is a powerful insulin sensitizer, but serious toxicities have curtailed its widespread
clinical use. Rosi functions as a high-affinity ligand for PPARgamma, the adipocyte-predominant nuclear
receptor (NR). The classic model of NR action, involving binding of ligand to the NR on DNA, explains
positive regulation of gene expression, but both ligand-dependent transcriptional repression and indirect
regulation are not well understood. We have addressed these issues by studying the direct effects of
rosiglitazone on gene transcription, using global run-on sequencing (GRO-seq). Rosi-induced changes in
gene body transcription were pronounced after 10 minutes and correlated with steady-state mRNA levels
as well as with transcription at nearby enhancers (eRNAs). Up-regulated eRNAs occurred almost
exclusively at PPARg binding sites, to which rosi treatment recruited coactivators including MED1, p300,
and CBP, without changes in binding of the corepressor NCoR. By contrast, down-regulated eRNAs fell in
sites devoid of PPARg but enriched for a variety of other TFs in the C/EBP and AP-1 families. These
enhancers lost coactivator binding upon rosi treatment, suggesting that rosi treatment causes
redistribution of coactivators to PPARg sites and away from enhancers containing other TFs, leading to
transcriptional repression at these eRNAs and their target genes. We also investigated the function of
MRL-24, a compound that has been shown to lack PPARg transactivation activity and regulate a distinct
subset of PPARg target genes while functioning as an equally effective insulin sensitizer as rosi. Though
our goal was to identify whether MRL-24 regulates the same functional enhancers marked by eRNAs as
rosi, we instead found that MRL-24 does not control a distinct subset of target genes, but rather acts as a
partial agonist for PPARg. Together, these studies further our understanding of transcriptional regulation
by modulation of PPARg activity, including insights into determining functional enhancers and
mechanisms of transcriptional repression by activation of a NR.
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ABSTRACT
REGULATION OF ADIPOCYTE TRANSCRIPTION BY PPAR
LIGANDS
Sonia E. Step
Mitchell A. Lazar

Rosiglitazone (rosi) is a powerful insulin sensitizer, but serious toxicities have curtailed
its widespread clinical use. Rosi functions as a high-affinity ligand for PPAR, the
adipocyte-predominant nuclear receptor (NR). The classic model of NR action,
involving binding of ligand to the NR on DNA, explains positive regulation of gene
expression, but both ligand-dependent transcriptional repression and indirect regulation
are not well understood. We have addressed these issues by studying the direct effects of
rosiglitazone on gene transcription, using global run-on sequencing (GRO-seq). Rosiinduced changes in gene body transcription were pronounced after 10 minutes and
correlated with steady-state mRNA levels as well as with transcription at nearby
enhancers (eRNAs). Up-regulated eRNAs occurred almost exclusively at PPAR binding
sites, to which rosi treatment recruited coactivators including MED1, p300, and CBP,
without changes in binding of the corepressor NCoR.

By contrast, down-regulated

eRNAs fell in sites devoid of PPAR but enriched for a variety of other TFs in the C/EBP
and AP-1 families. These enhancers lost coactivator binding upon rosi treatment,
suggesting that rosi treatment causes redistribution of coactivators to PPAR sites and
away from enhancers containing other TFs, leading to transcriptional repression at these
iv

eRNAs and their target genes. We also investigated the function of MRL-24, a compound
that has been shown to lack PPAR transactivation activity and regulate a distinct subset
of PPAR target genes while functioning as an equally effective insulin sensitizer as rosi.
Though our goal was to identify whether MRL-24 regulates the same functional
enhancers marked by eRNAs as rosi, we instead found that MRL-24 does not control a
distinct subset of target genes, but rather acts as a partial agonist for PPAR. Together,
these studies further our understanding of transcriptional regulation by modulation of
PPAR activity, including insights into determining functional enhancers and
mechanisms of transcriptional repression by activation of a NR.
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CHAPTER 1: General Introduction
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1.1 Diabetes and thiazolidinediones
Diabetes is a chronic disease that presents a growing burden on human health and the
world economy. An estimated 347 million people worldwide have diabetes, and this
number is expected to grow significantly in the coming decades (Danaei et al. 2011). Of
the drugs used to treat diabetes, thiazolidinediones (TZDs) are the only class that
functions primarily by improving insulin sensitivity. This class includes rosiglitazone
(Avandia) and pioglitazone (Actos). Several large-cohort studies have demonstrated the
efficacy of TZDs in improving glycemic control and preventing diabetes (Kahn et al.
2006; DeFronzo et al. 2011), but other trials showed an association with adverse effects,
including cardiovascular risk, fractures, and bladder cancer (Nissen and Wolski 2007;
Colhoun et al. 2012; Neumann et al. 2012). Based on these studies, in 2010 the FDA
placed restrictions on the prescription and use of rosiglitazone (rosi), due primarily to
concerns of increased risk of myocardial infarction. However, the FDA reversed this
decision in 2013 after a randomized study designed specifically to assess cardiovascular
risk on rosi was reanalyzed and no increased risk of heart attack or death was found
(Mahaffey et al. 2013). These clinical studies demonstrate that TZDs have tremendous
potential to aid in glycemic control, but their adverse effects have hindered widespread
use. Gaining a better understanding of their mechanism of action may help in developing
better drugs with fewer side effects.
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1.2 The function of the nuclear receptor PPAR
1.2a Enhancer function and regulation
Specialization of cells in development and signal response is critical for organismal
function. This regulation depends on the ability of cells to activate specific gene
expression patterns in response to environmental cues. Enhancers are the key genetic
elements that control cell-specific gene expression; they were first described as DNA
elements that act over a distance and in any orientation to increase gene expression
(Banerji et al. 1981). Though most of our knowledge about enhancer function comes
from studies of individual loci, novel techniques have recently allowed for the detection
of putative enhancer elements genome-wide and across cell types. Enhancers are usually
a few hundred base pairs long, located in distal intergenic regions, and lack a unifying
sequence composition (Buecker and Wysocka 2012). They do, however, contain specific
recognition sequences for transcription factor (TF) binding. Tens of thousands of putative
enhancers have been identified in different cell types, based on markers including histone
modifications, coactivator occupancy, or TF binding (Xie and Ren 2013).

Such studies have also demonstrated that many different TFs tend to colocalize on a
genome-wide scale in a given cell type (Chen et al. 2008), whereas the same factor in
different cell types or across developmental stages binds in different locations (Odom et
al. 2004). Enhancer activity appears to depend on relatively simple combinations of
lineage-determining transcription factors (Heinz et al. 2010). Cooperative binding of
3

transcription factors to closely clustered response elements in closed chromatin regions
increases chromatin accessibility to additional TFs, and causes the recruitment of
coactivators such as histone remodeling complexes. Specific histone marks have been
linked to active enhancers, including H3K4me1, H3K27ac, and H3K9ac (Buecker and
Wysocka 2012). Thus, genome-wide studies that aim to define enhancer elements
generally rely on the enrichment of these histone marks, the presence of coactivators such
as CBP and p300, the occupancy of RNA Polymerase II, or the strong binding of a
lineage-determining TF.

Though several mechanisms have been proposed for communication between a distal
enhancer and its target promoter, the one with the most supporting evidence is the model
of spatial colocalization, in which the enhancer and promoter are physically brought
together, with the intervening chromatin looped out (Kleinjan and van Heyningen 2005).
The presence of chromatin looping has now been tested in many models by experiments
such as chromatin conformation capture (3C) (Dekker et al. 2002). These chromatin
loops are believed to drive the specificity of enhancer-promoter interactions, as well as
the phenomenon of transcription at enhancers, described below.

1.2b Nuclear receptors
Years after their anti-diabetic effects were established in animal models, TZDs were
shown to be high-affinity ligands for the TF peroxisome proliferator-activated receptor 
4

(PPAR) (Lehmann et al. 1995), a member of the nuclear receptor (NR) superfamily.
NRs are a large family of mostly ligand-dependent transcription factors that regulate
many aspects of physiology, including development and metabolism (Mangelsdorf et al.
1995).

All NRs share the same basic structure. The N-terminus contains the A/B domain,
followed by the DNA binding domain (DBD), the hinge region, and the ligand binding
domain (LBD) at the C-terminus (Helsen et al. 2012). The DBD consists of two zincfinger elements, which confer sequence specificity to the hexanucleotide response
element that each NR recognizes, known as a half-site. The LBD contains an interior
pocket specific to the ligand it binds, as well as a ligand-dependent activation function
domain (AF-2). AF-2 consists of several helices including helix 12, and is capable of
recruiting transcriptional coactivators (Shiau et al. 1998). Ligands regulate the
recruitment of coactivators via the LBD by altering the conformation of helix 12. In the
absence of agonist, the conformation of the LBD creates a different binding surface,
favoring corepressor recruitment (Bain et al. 2007).

The NR family is divided into three classes (Bain et al. 2007). The first class is steroid
receptors, including estrogen receptor (ER), androgen receptor (AR), and glucocorticoid
receptor (GR). These NRs are located in the cytoplasm in the absence of ligand, and the
presence of ligand causes them to dissociate from heatshock proteins, translocate to the
5

nucleus, and bind to their response elements. The second class is the thyroid/retinoid
family, which includes thyroid receptor (TR) and retinoic acid receptor (RAR). These
NRs are constitutively bound to DNA, and the presence of ligand causes a
conformational change in helix 12, leading to the recruitment of coactivators and
activation of transcription. The last class is that of orphan nuclear receptors, such as
REV-ERB and ROR, which were discovered based on sequence homology and have no
known physiological ligands. Many orphan nuclear receptors have been “adopted” since
their discovery when their ligands were identified.

NRs regulate transcription through ligand-controlled recruitment of coregulators. Most
coregulators function as multi-unit protein complexes that regulate transcription by
modifying chromatin (Millard et al. 2013). The best-understood chromatin modifications
include histone acetylation and DNA methylation. Coactivator complexes often include
histone acetyltransferases (HATs), such as CBP and p300, as well as other factors that
recruit transcriptional machinery or favor promoter looping. Corepressor complexes often
contain the nuclear corepressors NCoR and SMRT, as well as histone deacetylases
(HDACs).

1.2c The role of PPAR in TZD function and insulin sensitivity
The expression of PPAR is dramatically induced during adipogenesis and the gene is
expressed predominantly in adipose tissue (Chawla and Lazar 1994; Tontonoz et al.
6

1994a). PPAR is necessary (Rosen et al. 1999) and sufficient (Tontonoz et al. 1994b) for
adipogenesis, and is also critical for the functions of mature adipocytes including lipid
metabolism, adipokine secretion, and insulin sensitivity (Rangwala and Lazar 2004).

PPAR, like most NRs, is a ligand-dependent transcription factor (Glass and Rosenfeld
2000). TZDs contribute to insulin sensitivity by acting on adipose tissue PPAR to
regulate gene transcription both positively and negatively. For example, TZDs induce
insulin sensitizing factors adiponectin (Maeda et al. 2001) and FGF-21 (Moyers et al.
2007), while suppressing the expression of genes promoting insulin resistance, including
TNF(Hofmann et al. 1994, resistin (Steppan et al. 2001), and retinol binding protein 4
(Yang et al. 2005). The most potent TZD in the clinic is rosi (Lehmann et al. 1995),
which has durable antidiabetic effects but, unfortunately, its use has been limited by its
toxicities. Because PPAR expression in adipose tissue is required for the in vivo
systemic insulin sensitizing effects of TZDs (Chao et al. 2000; He et al. 2003), it is
critical to understand how rosi binding to PPAR modulates gene expression.

Among the antidiabetic drugs, TZDs are unique in their ability to effectively improve
insulin sensitivity. The major organs that respond to insulin are skeletal muscle, liver, and
adipose tissue but the direct effects of TZDs are believed to be mainly in adipose tissue
for several reasons. First, adipose tissue has by far the highest levels of PPAR, about
ten-fold higher than in muscle (Chawla et al. 1994). Second, mice lacking adipose tissue
7

or PPAR in adipose do not respond to TZD treatment (Chao et al. 2000; He et al. 2003).
Fat-specific PPAR knock-out mice have almost complete lipoatrophy and severe insulin
resistance (Wang et al. 2013). Mice lacking PPAR in liver or muscle, however, retain
their response to the insulin sensitizing effects of PPAR (Matsusue et al. 2003; Norris et
al. 2003). These results indicate that TZDs act primarily on adipose tissue, which in turn
signals to the peripheral tissues to improve insulin sensitivity.

1.2d Transcriptional regulation by PPAR
There are two PPAR isoforms, 1 and 2. They are nearly identical except for different
N-terminals due to different start sites and first exons (Chawla et al. 1994; Tontonoz et al.
1994a), and they are believed to have the same function. PPAR binds to specific DNA
sequences known as PPAR response elements (PPREs) and heterodimerizes with another
nuclear receptor, retinoid X receptor (RXR). Studies into the genome-wide binding of
PPAR and members of the CCAAT/enhancer-binding protein (C/EBP) family
demonstrated that these TFs bind cooperatively near most genes up-regulated during
adipogenesis, suggesting that they coordinate the activation of genes that determine
adipocyte biology (Lefterova et al. 2008; Nielsen et al. 2008). Bioinformatic analysis of
PPAR:RXR binding sites in these studies showed that the heterodimer binds selectively
to a degenerate direct repeat 1 (DR1) element, in which two direct repeats of the NR halfsite (AGGTCA) are separated by one nucleotide. Binding of rosi to PPAR results in the
increased recruitment of coactivators, including SRC-1, CBP, p300, and MED1, that
8

function to induce gene expression (Westin et al. 1998; Gelman et al. 1999; Ge et al.
2002; Bugge et al. 2009).

1.3 MRL-24 as a non-agonist ligand of PPAR
Some alternative mechanisms have been proposed to explain how TZDs exert their
antidiabetic effects. In a mouse model of diet-induced obesity, Cdk5 was shown to
specifically phosphorylate PPAR at Ser-273 in adipose tissue (Choi et al. 2010). Though
this modification did not alter general PPAR transcriptional activity, it resulted in altered
transcription of a subset of target genes. Treatment with TZDs inhibited this
phosphorylation both in vivo and in vitro. The phosphorylation was also inhibited by
MRL-24, a PPAR ligand that is a poor agonist in transactivation assays but an effective
anti-diabetic agent in mice (Acton et al. 2005). Indeed, treating mice with MRL-24 in
these studies improved glucose tolerance but only caused differential gene expression
changes in a subset of PPAR target genes. These studies suggested that some PPAR
pathways exist that may be able to dissociate the positive metabolic effects from the
adverse effects seen with TZDs.

9

1.4 Mechanisms of nuclear receptor-mediated transcriptional repression
1.4a Transrepression
Though binding of rosi to PPAR results in recruitment of coactivators to increase gene
expression, the mechanism by which rosi represses transcription is not well understood.
Genes repressed by rosi are likely to play an important role in its metabolic effects,
including genes such as TNF and resistin. There are several mechanisms that may
explain NR-mediated transcriptional repression.

One such suggested mechanism is transrepression, which has been demonstrated in the
setting of rosi-treated macrophages (Pascual et al. 2005). In these cells, the corepressor
NCoR is recruited to pro-inflammatory genes, including some chemokines and inducible
nitric oxide synthase, by TFs such as AP-1 and NF-B. Treatment with the endotoxin
lipopolysaccharide (LPS) causes activation of these genes through dismissal of the
corepressor complex and recruitment of a coactivator complex. Co-treatment with rosi
and LPS, however, causes transrepression: rosi causes SUMOylation of PPAR, which
tethers to NCoR, prevents its dismissal from the gene promoter, and blocks gene
activation. This mechanism, however, has not been shown in other cell types, has only
been demonstrated at individual genes rather than genome-wide, and only explains the
ability of rosi to block LPS-mediated gene induction, rather than the ability of rosi to
repress genes directly (Glass and Saijo 2010).

10

A very similar transrepression mechanism was confirmed for liver X receptor (LXR) in
macrophages, which represses an overlapping but separate set of inflammatory genes.
Similar to PPAR, ligand-dependent SUMOylation of LXR blocks NCoR clearance from
the promoter, preventing gene induction (Ghisletti et al. 2007).

A number of studies have also found that glucocorticoid receptor (GR) can have
suppressive effects on immune function through transrepression. In one study, GR was
able to suppress inflammatory gene activation by recruiting the coactivator GRIP1
(Rogatsky et al. 2002). Though usually a coactivator, GRIP1 functions as a corepressor in
a complex with GR tethered to AP-1 or NF-B and blocks activation of immune genes.
Other mechanisms for transrepression by GR have been suggested, including that GR
tethering to NF-B blocks its ability to recruit the essential coactivator IRF3 (Ogawa et
al. 2005) and positive transcription elongation factor b (pTEFb) (Luecke and Yamamoto
2005), both of which are required for activation of gene transcription.

1.4b Ligand-dependent corepressor recruitment
In some cases, nuclear receptors that normally function as transcriptional activators have
been shown to repress transcription by recruiting corepressor complexes. For example, in
microglia and astrocytes in the brain, the orphan nuclear receptor Nurr1 inhibits
activation of inflammatory genes by docking to NF-B and recruiting the CoREST
corepressor complex (Saijo et al. 2009). In another study more relevant to adipocyte
11

biology, TZDs were shown to repress certain “visceral white” genes (and promote the
“browning” phenotype) by recruiting the corepressors CTBP1 and CTBP2 to C/EBP,
and PPAR was required for this process (Vernochet et al. 2009). Additionally, the
cofactor RIP140 was shown to be able to function as a corepressor and inhibit
transcription by binding to nuclear receptors including TR and ER (Lopez et al. 1999).

1.4c Competitive binding
In another mechanism, nuclear receptors can inhibit transcription by competing for the
same binding site as another transcription factor that may be a stronger transactivator in
that context. For example, glucocorticoids antagonize E2-stimulated ER gene
expression in MCF-7 cells. When the cells were co-treated with dexamethasone and E2,
GR was found to bind to estrogen binding sites, displacing ER and its coactivator
steroid receptor coactivator 3 (SRC3), leading to the repression of ER target genes
(Karmakar et al. 2013). Binding of GR to these sites requires protein-protein interactions
with ER, FOXA1, and AP1. Similarly, estrogen-related receptor alpha (ERR)
suppresses the expression of the hydroxysteroid sulfotransferase gene SULT2A1 in
human liver carcinoma HepG2 cells by competing for binding to inverted repeat IR2 and
DR4 elements with other nuclear receptors, including vitamin D receptor (VDR) and
constitutive androstane receptor (CAR) (Huang et al. 2011). In other cases, a NR binds to
a response element that overlaps the binding site for another TF, precluding binding and
leading to transcriptional repression. This has been demonstrated at the osteocalcin
12

promoter, in which the GRE overlaps with the TATA box such that GR binding prevents
binding of TFIID (Stromstedt et al. 1991). Similarly, during adipogenesis ROR can
block induction of the perilipin gene by binding to a response element that overlaps with
the PPAR element in the promoter, thus blocking PPAR-mediated gene transcription
(Ohoka et al. 2009).

1.4d Coactivator redistribution
Another important proposed mechanism to explain transcriptional repression driven by
TFs is coactivator redistribution, also referred to as “squelching.” This model posits that
general coactivators are at a limiting concentration in the nucleus such that when one TF
is activated and recruits additional coactivators, those coactivators are necessarily lost
from other TFs, leading to transcriptional repression. This idea has been around for more
than 25 years, since Mark Ptashne demonstrated that overexpressing GAL4 in yeast
inhibited transcription of genes lacking GAL4 binding sites (Gill and Ptashne 1988).
They attributed this inhibition to the ability of GAL4 to sequester away key components
of the transcriptional machinery and termed this phenomenon “squelching.” Since then,
coactivator redistribution has been demonstrated in many models, though primarily in in
vitro systems relying on overexpression.

It was later shown, for example, that activation of a number of nuclear receptors
(including retinoic acid receptor [RAR], RXR, ER, and thyroid hormone receptor [TR])
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and subsequent inhibition of AP-1 depend on the coactivators CBP and p300, apparently
as a result of their limiting concentration (Kamei et al. 1996). Similarly, in LNCaP cells
the coactivator CBP was shown to be necessary for androgen receptor (AR) function and
its ability to inhibit AP-1 function, likely due to its limiting amount (Fronsdal et al.
1998). There is also evidence that PPAR may cause transcriptional repression through
coactivator redistribution: in macrophages, PPAR inhibits gene induction by LPS, and
this effect is dependent on the ability of PPAR to interact with CBP (Li et al. 2000).
Another study demonstrated that RAR and RXR can inhibit transactivation by the TF
serum response factor (SRF) because of competition for a limiting concentration of p300
and the coactivator SRC-1 (Kim et al. 2001).

All of the studies mentioned above were performed in in vitro systems, with methods
including overexpression and pull-downs to determine binding interactions, and
luciferase assays to measure transactivation, often at a single gene promoter. However, a
more recent paper demonstrated this effect using chromatin immunoprecipitation (ChIP)
for endogenous TFs and coactivators on DNA on a genome-wide scale (He et al. 2012).
In this study, estradiol (E2) treatment of MCF-7 cells caused not only an increase in ER
binding, but also an increase in DNaseI hypersensitivity (DHS), a measure of chromatin
accessibility, at the same sites, as well as increased transcription at nearby genes. Sites
bound by the TF FOXA1 but not ER, however, had a decrease in DHS. The change in
DHS is linked not to changes in FOXA1 binding strength but to changes in binding of the
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coactivator NCOA3. On a genome-wide level, sites with ER binding and E2-increased
DHS have increased NCOA3 binding, while sites with FOXA1 but not ER and E2decreased DHS have decreased NCOA3 levels. This supports a model in which E2
treatment causes recruitment of the coactivator NCOA3 to ER sites, leading to a loss of
coactivator from other TFs such as FOXA1 and subsequent transcriptional repression.

1.5 GRO-seq and non-coding RNAs
1.5a GRO-seq and nascent transcripts
Global run-on followed by sequencing (GRO-seq) is a technique that identifies nascent
transcripts in a genome-wide manner (Core et al. 2008). This approach can detect nearinstant changes in transcription levels, allowing the discrimination of direct
transcriptional targets from secondary ones. It also provides stranded information to
detect sense and anti-sense transcripts, including divergent transcription. Importantly, it
also allows for the discovery of novel, un-annotated transcripts outside of RefSeq genes.

For example, GRO-seq was used to determine the immediate effects of estrogen on the
transcriptome of MCF-7 cells (Hah et al. 2011). Estrogen was found to rapidly and
transiently regulate 25% of the transcriptome, including many previously unannotated
transcripts, with many transcripts regulated as early 10 minutes after treatment. One of
the classes of regulated transcripts was intergenic transcripts; among those, the ones that
15

fell in ER enhancers were mostly up-regulated by E2 treatment, while the others were
mostly down-regulated. As expected, regulation of nascent protein-coding transcripts
correlated with steady-state levels of the corresponding mRNA, as measured by
microarray or RT-qPCR, but with temporal delay. rRNA and tRNA genes were also
increased, suggesting an up-regulation of protein biosynthetic machinery in response to
estrogen treatment. In addition, genes that were up-regulated after 10 or 40 minutes of
treatment were significantly enriched for ER binding sites within 10kb of the
transcription start site (TSS), whereas those up-regulated after 160 minutes were not,
suggesting that these were in many cases secondary targets.

GRO-seq has also been used in several instances (Wang et al. 2011; Hah et al. 2013; Lam
et al. 2013; Li et al. 2013) to identify enhancer RNAs, which are described in more detail
below in section 1.5b and 1.5c.

1.5b lncRNA and eRNA function
Novel technologies of the genomic era have demonstrated that much more of the
mammalian genome is transcribed than the 1-2% occupied by coding genes. These noncoding transcripts have been termed the “dark matter” of the genome (Johnson et al.
2005). One class of non-coding transcripts is long non-coding RNAs (lncRNAs), which
are defined as intergenic transcripts longer than 200 bp. Thousands of lncRNAs have
been identified so far and the number is growing (Cabili et al. 2011). There are many
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examples of well-characterized lncRNAs that play an important role in development or
disease, including Xist in X-inactivation (Sotomaru et al. 2002) and HOTAIR in transacting gene regulation (Gupta et al. 2010). Nevertheless, the vast majority of lncRNAs
are not evolutionarily conserved, are expressed at very low levels, and may represent
transcriptional noise (Struhl 2007).

For the lncRNAs that have been shown to have a biological function, several mechanisms
have been demonstrated, including interactions with protein, RNA, and DNA. lncRNAs
can recruit protein complexes via specific RNA:protein interactions, such as in the case
of Xist, which interacts with the polycomb repressive complex to silence one of the X
chromosomes in vertebrates (Zhao et al. 2008). A lncRNA can also act as a scaffold,
bringing two or more proteins together into a complex; for example, HOTAIR brings
together several components of a repressive complex through specific modular
interactions with its 5’ and 3’ ends (Tsai et al. 2010). lncRNAs can also interact with
other RNAs, including by binding to an mRNA in an antisense manner to regulate its
translation or degradation (Carrieri et al. 2012), or by acting as a “sponge” for a miRNA
and thereby regulating expression of the corresponding mRNA (Cesana et al. 2011).
Lastly, lncRNAs can act as guides or decoys to regulate transcription or epigenetic
modifications. For example, the lncRNA NeST acts as a guide for the histone H3 lysine 4
methyltransferase complex and brings it to specific loci (Gomez et al. 2013), whereas
Lethe functions as a decoy by binding to components of the NF-B complex and
preventing them from binding to gene promoters (Rapicavoli et al. 2013).
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A sub-family of lncRNAs that are transcribed from enhancer elements, known as
enhancers RNAs (eRNAs), have also been of particular interest. Enhancers depend on the
binding of lineage-determining TFs, which recruit chromatin remodeling complexes to
activate transcription (Heinz et al. 2010).

Though transcription originating from an enhancer element was first demonstrated close
to 25 years ago at the locus control region near the beta-globin gene (Collis et al. 1990),
the genome-wide pervasiveness of enhancer transcription only became clear in 2010 due
to high-throughput techniques (De Santa et al. 2010; Kim et al. 2010). eRNAs can be
poly-adenylated or non-polyadenylated and can be either unidirectional or bidirectional
(Kim et al. 2010; Hah et al. 2011; Wang et al. 2011). They are transcribed from putative
enhancer regions, which can be characterized by high levels of H3K4me1 and H3K27ac,
binding of CBP and p300, and binding of lineage-determining TFs (Heintzman et al.
2009).

Interestingly, eRNAs are dynamically regulated in a signal-dependent manner, including
in response to depolarization of neurons (Kim et al. 2010) or estrogen treatment in breast
cancer cells (Hah et al. 2011). Additionally, signal-dependent changes in eRNA levels are
highly correlated with corresponding changes in transcription of nearby genes. Several
hypotheses for the role or function of eRNAs have been postulated (Natoli and Andrau
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2012), some or all of which may be true for different eRNAs. The first is that eRNAs are
noise, reflecting the collision of transcriptional machinery with accessible genomic
regions, or with regions that are brought close to promoters through chromatin looping.
The second is that the process of eRNA transcription may be important in changing
chromatin accessibility at specific sites. Lastly, the eRNA transcripts themselves may be
functional, by interacting with RNA or protein in cis or trans to regulate transcription
similarly to lncRNAs.

In the past two years, there has been mounting evidence for the last hypothesis: that
eRNAs may function to promote transcription of nearby genes. Targeted ablation of
eRNAs by small interfering RNA (siRNA), antisense oligonucleotides (ASO), and locked
nucleic acids (LNA) caused decreased expression of nearby genes in several models
(Lam et al. 2013; Li et al. 2013; Melo et al. 2013; Mousavi et al. 2013). Furthermore,
artificially tethering an eRNA to a promoter increased transcription of the target gene
(Melo et al. 2013). The question of how eRNAs may be contributing to enhancer function
or increasing gene transcription still remains open, though potential mechanisms include
increased chromatin looping and increased recruitment of transcriptional machinery,
chromatin modifiers, or coregulators (Lam et al. 2014).
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1.5c eRNAs mark functional enhancers
Despite several examples of eRNAs functioning to promote target gene transcription,
controversy remains as to whether the vast majority of eRNAs have a functional role.
Independent of the question of whether eRNA transcripts serve a function, however, there
is increasing evidence that eRNA transcription marks functional enhancers. For example,
ER binding sites containing eRNAs are enriched for enhancer elements compared to
binding sites without eRNAs, including coactivator binding, H3K4me1, DNase I
hypersensitivity, and chromatin looping by chromatin interaction analysis by paired-end
tag sequencing (ChIA-PET) (Hah et al. 2013). Furthermore, using eRNAs as predictors
of enhancer function is more effective than using H3K4me1 or H3K27ac, where the
measure of enhancer function is either chromatin looping or CBP occupancy.
Additionally, blocking eRNA elongation with flavopiridol does not affect enhancer
function, suggesting that at least in the case of the specific enhancers tested in this
experiment, the eRNA transcript is not critical for enhancer function. The first paper to
describe genome-wide eRNA transcription also noted that knocking out a gene promoter
ablates the associated eRNA, which suggests that an interaction with the promoter, such
as a chromatin loop, is necessary for eRNA production (Kim et al. 2010). Lastly, another
study also showed in both IMR90 and mESC cells that eRNA transcription is a more
reliable indicator of enhancer activity than H3K27ac is, where enhancer activity was
defined by transcription of the nearest gene (Zhu et al. 2013). Together these studies
suggest that in the context of tens of thousands of putative enhancers defined by TF
binding or chromatin marks, eRNA production can serve as a useful marker of functional
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enhancers that are actually playing a role in regulating gene transcription in a signaldependent manner.

1.6 Aims of thesis
It has been known for many years that TZDs bind to PPAR in adipose tissue, causing an
improvement in insulin sensitivity. Though their molecular target is known, however, the
molecular mechanism of TZD action is still not well understood. The aim of this thesis is
to expand our understanding of the transcriptional regulation of adipocytes by TZDs and
PPAR.

Previous methods to identify gene targets of rosi treatment relied on microarray or RNAseq, which measure steady-state mRNA levels after a longer period of time. This
conflates immediate transcriptional targets with secondary, indirect targets. In Chapter 2,
direct transcriptional targets of rosi treatment are identified by using GRO-seq after short
time points of rosi treatment. This allows us to determine the relationship between
nascent pre-mRNA targets and steady-state mRNAs, identify gene targets that are likely
due to secondary effects, and confirm that virtually all direct transcriptional up-regulation
is due to PPAR activity.
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In Chapter 3, eRNAs are identified and used to determine functional regulatory elements
that are important to rosi-regulation. Though rosi has previously been shown to cause a
dismissal of corepressors and a recruitment of coactivators at certain sites (Guan et al.
2005), changes in coregulator occupancy has never been demonstrated genome-wide, and
the effects of rosi on histone marks were unknown. Furthermore, there has been very
little insight into rosi-mediated repression of gene transcription. In this aim, the
regulation of eRNAs is used to focus on functional enhancers and correlated with other
changes – coactivator and corepressor recruitment, histone marks, and binding of other
TFs – to gain a better understanding of the mechanisms of transcriptional regulation by
rosi in a dynamic manner.

The promise of insulin-sensitizing effects of TZDs along with concern for their serious
adverse effects have driven a continued interest in studying selective PPAR modulators,
or SPPARMs. For example, the compound MRL-24 has been demonstrated to improve
insulin sensitivity in mice despite lacking agonist ability in transactivation studies and
activating a distinct subset of PPAR target genes (Choi et al. 2010). In Chapter 4,
transcriptional regulation by MRL-24 is studied in a different model of adipocytes in an
attempt to confirm its unique set of target genes and determine whether it acts by
regulating a distinct group of PPAR enhancers. In this aim, we demonstrate that at least
in the 3T3-L1 model of adipocytes, MRL-24 does not in fact up-regulate a unique set of
target genes, but rather acts as a partial agonist to regulate many of the same genes as rosi
but to a lesser degree. Chapter 5 summarizes the studies and discusses future directions.
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CHAPTER 2: Regulation of nascent gene transcripts and mRNAs by
rosiglitazone

Published in part in Genes & Development, 2014 May 1;28(9):1018-28.

The text, figures, and legends in this chapter were the work of Sonia Step with the
following exceptions. Andreas Prokesch performed the gene expression microarray
experiment. Hee-woong Lim conducted the data processing and bioinformatics analyses.
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2.1 Introduction
PPAR is a nuclear receptor that is dramatically induced during adipogenesis and
expressed predominantly in adipose tissue (Chawla and Lazar 1994; Tontonoz et al.
1994a). It is necessary (Rosen et al. 1999) and sufficient (Tontonoz et al. 1994b) for
adipogenesis, and also critical for the functions of mature adipocytes, including lipid
metabolism, adipokine secretion, and insulin sensitivity (Rangwala and Lazar 2004).
PPAR binds near most adipogenic genes as a heterodimer with RXR (Lefterova et al.
2008; Nielsen et al. 2008).

PPAR, like most NRs, is a ligand-dependent transcription factor (Glass and Rosenfeld
2000). High affinity ligands for PPAR include the TZDs (Lehmann et al. 1995), which
are insulin-sensitizing drugs (Nolan et al. 1994). TZDs contribute to insulin sensitization
by acting on adipose tissue to regulate gene transcription both positively and negatively.
For example, TZDs induce insulin sensitizing factors adiponectin (Maeda et al. 2001) and
FGF-21 (Moyers et al. 2007), while suppressing the expression of genes promoting
insulin resistance, including TNF (Hofmann et al. 1994), resistin (Steppan et al. 2001),
and retinol binding protein 4 (Yang et al. 2005). The most potent TZD in the clinic is
rosiglitazone (rosi) (Lehmann et al. 1995), which has durable antidiabetic effects but,
unfortunately, has toxicities that limit its widespread use (Kung and Henry 2012;
Ahmadian et al. 2013). Because PPAR expression in adipose tissue is required for the in
vivo systemic insulin sensitizing effects of TZDs (Chao et al. 2000; He et al. 2003), it is
critical to understand how rosi binding to PPAR modulates gene expression.
24

Many studies have used transcriptome analysis to infer the effects of rosi on steady state
gene expression in adipocytes (Li and Lazar 2002; Sears et al. 2007; Choi et al. 2010;
Rong et al. 2011). However, steady state mRNAs levels are determined both by their
rates of transcription and degradation. Here, for the first time, we have directly measured
rates of adipocyte transcription genome-wide, using global run-on followed by
sequencing (GRO-seq) (Core et al. 2008). We find that rosi rapidly up- or downregulates
the transcription of thousands of adipocyte genes, and this regulation correlates highly
with steady state mRNA regulation. We can also separate out direct gene targets that are
up-regulated within 30 minutes or 1 hour of treatment from other genes that are not direct
targets but are up-regulated at later time points, suggesting indirect or non-transcriptional
regulation.

2.2 Materials and Methods
2.2a Cell Culture
3T3-L1 cells were obtained from American Type Culture Collection and grown in
DMEM (Invitrogen) supplemented with 10% fetal bovine serum (Tissue Culture
Biologics), 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen). Two days postconfluence differentiation media was added, consisting of growth media with 1 μM
dexamethasone, 10 μg/ml human insulin, and 0.5 mM 3-isobutyl-1-methylxanthine
(Invitrogen). Cells were differentiated as described previously (Lefterova et al. 2008), by
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growth in differentiation media for 2 days, followed by growth media with insulin for 2
days, followed by growth media only. When indicated, mature 3T3-L1 adipocytes were
treated with 1μM rosiglitazone (Biomol) dissolved in DMSO.

2.2b Gene expression analysis
RNA was isolated from cells using TRIzol (Invitrogen), followed by the RNeasy Mini
Kit (Qiagen). RT-PCR was performed using 1 μg RNA (Applied Biosystems) following
manufacturer’s instructions, and qPCR was performed using primers listed in Table 2.1
using Power SYBR Green Master Mix (Applied Biosystems) on the PRISM 7500 and
7900HT instruments (Applied Biosystems). Analysis was performed using the standard
curve method, and all genes were normalized to the housekeeping gene Arbp. For the
microarray, RNA integrity was examined using an Agilent 2100 Bioanalyzer. RNA
samples (150 ng) with RNA integrity number >7 were used for target amplification and
labeling via the Ambion WT Expression kit (#4411974) and Affymetrix WT Terminal
Labeling kit (#900671) following manufacturer’s protocol. Mouse Gene 1.1 ST Array
Plates (#901418, Affymetrix) were used for microarray hybridization, wash, stain and
scan with GeneTitan hyb-wash-stain kits (#901622, Affymetrix) and a GeneTitan
instrument. GeneTitan scanner data were collected with default parameters and further
analyzed using Partek Genomics Suite. Data were normalized using default RMA
method. For each gene, an average was taken across replicates for the comparative
analysis with GRO-seq gene transcriptional level.
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2.2c GRO-seq library preparation
GRO-seq was performed as previously described (Core et al. 2008; Wang et al. 2011).
Cells were washed twice with ice-cold PBS, then swelled in swelling buffer (10 mM Tris
pH 7.5, 2 mM MgCl2, 3 mM CaCl2) for 5 min on ice. Cells were centrifuged at 400g for
10 min, then resuspended in lysis buffer (swelling buffer with 10% glycerol and 1%
Igepal) and incubated on ice for 5 min. Nuclei were washed twice with lysis buffer, then
resuspended in freezing buffer (50 mM Tris pH 8.3, 40% glycerol, 5 mM MgCl2, 0.1 mM
EDTA). Nuclei were counted, pelleted, and 5 x 106 nuclei were resuspended in 100 μl
freezing buffer. For each library, run-on was performed on 4 tubes of 5 x 106 nuclei.

For the run-on, cells were mixed with an equal volume of run-on buffer (10 mM Tris pH
8.0, 5 mM MgCl2, 1 mM DTT, 300 mM KCl, 20 units of SUPERase-In, 1% Sarkosyl,
500 μM ATP, GTP and Br-UTP, 2 μM CTP) and incubated for 5 min at 30°C. Nuclear
RNA was extracted with TRIzol (Invitrogen) and precipitated with NaCl and ethanol
overnight. The pellet was resuspended in water and the RNA was DNase treated
(Ambion) for 30 min. RNA was hydrolyzed using fragmentation reagents (Ambion) for
13 min at 70°C and purified through a Micro Bio-Spin p-30 column (Bio-Rad) according
to manufacturer’s instructions. RNA was treated with 1.5μl T4 polynucleotide kinase
(New England Biolabs) for 1h at 37°C, then with an additional 1μl for 1h more. RNA
was denatured for 5 min at 65°C.
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Anti-BrU agarose beads (Santa Cruz) were rotated for 1h in blocking buffer (0.5x SSPE,
1 mM EDTA, 0.05% Tween-20, 0.1% PVP, and 1 mg/ml BSA). Run-on RNA was
rotated with beads for 1h, followed by washes twice in binding buffer (0.5x SSPE, 1 mM
EDTA, 0.05% Tween-20), twice in low salt buffer (0.2x SSPE, 1 mM EDTA, 0.05%
Tween-20), once in high salt buffer (0.5x SSPE, 1 mM EDTA, 0.05% Tween-20,
150 mM NaCl), and twice in TET buffer (TE pH 7.4, 0.05% Tween-20). BrU-labeled
RNA was eluted from the beads four times for 15 min with 100 μl elution buffer preheated to 42°C. RNA was ethanol-precipitated overnight.

Precipitated RNA was resuspended in water, denatured, and treated with poly(A)polymerase (NEB) for 30 min at 37°C. cDNA synthesis was performed as described
previously

(Wang

et

al,

Nature

2011)

using

oNTI223

primer

((5′-

pGATCGTCGGACTGTAGAACTCT;CAAGCAGAAGACGGCATACGATTTTTTTTT
TTTTTTTTTTTVN-3′) where the p indicates 5′ phosphorylation, ‘;’ indicates the abasic
dSpacer furan and VN indicates degenerate nucleotides. The reaction was treated with 3
μl exonuclease I (Fermentas) for 15 min at 37°C, followed by 2 μl 1M NaOH for 20 min
at 98°C, and neutralized with 1μl 2M HCl. cDNA was run on 10% TBE-urea gel, then
products were excised and eluted from shredded gel pieces for 4h in TE + 0.1% Tween
and precipitated in ethanol overnight. First-strand cDNA was circularized with
CircLigase (Epicentre), denatured for 10 min at 80°C, and relinearized with APE I
(NEB). Linearized DNA was amplified by PCR using Phusion Hot Start II Kit, according
to

manufacturer’s

instructions.

The

oligonucleotide
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primers

oNTI200

(5′-

CAAGCAGAAGACGGCATA-3′)

and

oNTI201

AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACG-3′)

(5′were

used for amplification. The PCR product was run on a 10% TBE gel and eluted as before.
Libraries were sequenced on an Illumina hi-Seq2000 with sequencing primer 5′CGACAGGTTCAGAGTTCTACAGTCCGACGATC-3′.

2.2d GRO-seq data processing
First, adapter and poly-A sequence were trimmed off from the raw tags, then remaining
tags were converted into FASTA format before alignment. Trimmed tags were aligned to
the mouse genome, mm8, using Bowtie (Langmead et al. 2009) with the following
options: inputs were in FASTA format (-f), three mismatches were allowed for each tags
(-v 3), and only uniquely mapped tags were retained (-m 1). All the alignments were
adjusted to 50bp by extending toward 3’-end if their size is shorter than that to make
libraries comparable. For the visualization of GRO-seq data, we pooled two replicates for
each time point then extended each tag to 150bp to make smooth profiles. bedGraph files
were generated first using genomeCoverageBed command in BEDTools suite (Quinlan
and Hall 2010) for plus and minus strands separately and they were converted to bigwig
format using bedGraphToBigWig command in BLAT suite (Kent et al. 2010).

2.2e ChIP-seq data processing
For PPAR, we used two public PPARChIP-seq data sets, GSM340799 and
GSM678393 (Nielsen et al. 2008; Schmidt et al. 2011) from Gene Expression Omnibus,
29

where all the redundant tags were eliminated in each data set and then the remaining tags
were pooled into a single data set. Peak-calling was performed using findPeaks command
in Homer (Heinz et al. 2010). After initial calling, all the peaks were resized to 200 bp,
then a 2 RPM cut-off was applied to select strong peaks.

2.2f Gene transcription analysis
To determine rosi-induced regulation of gene transcription, we used normalized tag
counts within a window between +0.5 kb and 12 kb of transcription start site (TSS) to
capture acute changes and yet minimize the bias from paused signal at promoters. When
counting tags, we ignored the tags aligned onto rRNA, snoRNA, snRNA, or tRNA to
avoid any false contribution to gene body GRO-seq signal due to these highly abundant
elements. To identify rosi-regulated genes, we performed an exact test with edgeR
package (Robinson et al. 2010) for each time point, 10 min, 30 min, 1h, and 3h using 0
min as a control. Genes were considered rosi-regulated if FDR < 0.05 at any time point,
but those with low GRO-seq signal (< 0.5 RPKM) or poor gene body coverage (< 70%)
at every time point were discarded before downstream analysis. Temporal patterns of
rosi-induced regulation were graphically presented by hierarchical clustering, where
GRO-seq levels were RPKM-normalized and 1−(correlation coefficient) were used as a
distance measure between genes. Initial dendrogram was first created based on Ward’s
criterion using fastcluster R package (Müllner 2011) then subjected to optimal leaf
ordering (Bar-Joseph et al. 2001). In the visualization of clustering heatmaps, RPKM
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values were converted into log2(fold-change over 0 min) for intuitive color representation
of up or down regulation.

2.3 Results
2.3a Rosiglitazone rapidly and robustly regulates gene transcription in adipocytes.
GRO-seq (Core et al. 2008; Wang et al. 2011) was used to measure nascent gene
transcription in mouse 3T3-L1 adipocytes and after treatment with rosi for 10 min, 30
min, 1h and 3h. The Fabp4 locus, a classic adipocyte PPAR gene target (Spiegelman
and Green 1980; Rival et al. 2004), showed increased transcription with rosi treatment
(Figure 2.1A). By contrast, transcription from the Rgs2 gene body was rapidly repressed
by rosi (Figure 2.1B), consistent with the behavior of the mRNA (Sears et al. 2007).
Overall, 1,951 annotated RefSeq genes were transcriptionally regulated by rosi at one or
more of the time points tested (Figure 2.1C). Interestingly, 71% of regulated nascent
transcripts were repressed whereas only 29% were activated by rosi.

2.3b Regulation of nascent gene transcription by rosi correlates with changes in mRNA
levels.
To assess the temporal and gene-specific relationship between nascent gene transcription
and steady-state mRNA levels, we determined the adipocyte transcriptome using gene
expression microarrays after 30 min, 1h, 2h, 6h, 12h, 24h, 36h, and 48h of rosi treatment,
with 3 biological replicates at each time point (Figure 2.2). While the nascent
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transcription of many genes was regulated as early as 10 and 30 minutes after rosi, very
few mRNA transcripts changed during this time period and for at least 2 hours after rosi
treatment. This was not surprising, as the time required to reach new steady state levels
is related to the rate of degradation rather than the rate of synthesis (Schimke and Doyle
1970). However, the correlation between nascent transcription and steady-state mRNA
levels was high at later time points, with the greatest correlation noted between the
transcription regulation at 3h and the mRNA regulation measured 6h after rosi. The lower
correlation with later microarray time points suggests that steady-state regulation at these
later times may be dependent on secondary transcriptional changes occurring later than
3h of treatment.

2.3c Some target genes may be regulated non-transcriptionally or by secondary effects.
Comparing rosi-regulation of pre-mRNAs and their corresponding steady-state mRNAs
by RT-qPCR suggests that despite the high correlation between transcription and mRNA
(Figure 2.2), many genes may also be regulated by different mechanisms or on different
timescales. While Fabp4 pre-mRNA is rapidly induced, Gyk pre-mRNA is not
significantly regulated despite induction of the mRNA, and Acaa1b pre-mRNA is not
significantly induced until later time points (Figure 2.3). These results suggest alternative
mechanisms that may regulate a subset of PPAR target genes, such as induction of
secondary transcription factors, or non-transcriptional regulation of mRNA degradation.
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2.3d Up-regulated genes are enriched for strength, number, and proximity of PPAR
binding sites.
PPAR binding is critical for the regulation of gene body transcription. Upregulated
genes were statistically significantly enriched for PPAR sites closer to the transcription
start site (TSS) compared to downregulated or unregulated genes (Figure 2.4A).
Furthermore, upregulated genes had significantly more PPAR binding sites within
100kb of the TSS (Figure 2.4B).

2.4 Conclusions
These studies provide a higher resolution and more dynamic portrait of rosi-regulated
gene transcription than previously possible. Earlier reports of rosi-regulated gene
expression using microarray or PolII ChIP-seq found a few hundred regulated genes, with
half or slightly more than half of those being upregulated by rosi (Choi et al. 2010;
Haakonsson et al. 2013). In contrast, we find that transcription is regulated at almost
2,000 gene bodies, more than two-thirds of which are repressed in response to ligand
treatment. We believe this increased sensitivity arises from the GRO-seq technique, as
well as from the use of multiple time points to capture various dynamics of direct
transcriptional regulation.

Rosi regulates nascent gene transcription within 10 minutes of treatment, and this
correlates well with steady state mRNA regulation. The correlation is delayed, as
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expected, since changes in gene body transcription precede those of the mRNAs, and
because the time to reach a new steady state mRNA level is independent of the rate of
synthesis and dependent solely on the mRNA half-life (Schimke and Doyle 1970). Thus,
while transcription changes quickly, very few changes in steady state mRNA levels are
seen earlier than 2h of rosi treatment. Interestingly, the highest correlation between
transcription and steady state mRNA is seen at the 3h GRO-seq and 6h microarray time
point, with a correlation coefficient of 0.773. Comparing the transcriptional regulation
after 3h of rosi with later microarray time points leads to lower and lower correlations at
later time points, suggesting that changes in mRNA levels after 24h or 36h are controlled
in part by early transcriptional changes, but also by other effects that we cannot detect by
GRO-seq after 3h of rosi treatment.

One phenomenon that may contribute to later mRNA changes that are not explained by
early transcriptional changes is secondary transcriptional regulation. It is possible that
among the many targets that rosi regulates, there may be genes that encode TFs. Even if
these are among its directly up-regulated targets, it would still take hours until their
protein levels increase. These TFs may then bind to DNA and regulate transcription after
12 to 24h of rosi treatment or later. This kind of secondary transcriptional regulation may
be important to the effects of longer rosi treatments on mRNA levels, and thus critical for
the physiological effects of rosi. As discussed in Section 5.2a, future studies could
investigate these presumed secondary effects that may contribute to the effects of rosi.
GRO-seq at later time points such as 24 or 36 hours would provide important additional
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information, such as which genes are regulated at later time points, and the mechanism of
these effects. Analysis of regulated eRNAs at later time points, similar to the work
described in Chapter 3, may suggest which enhancers and therefore which transcription
factors play a role in secondary effects of rosi.

In Figure 2.4, qPCR of pre-mRNAs and their corresponding mRNAs suggests that some
important targets may be regulated non-transcriptionally. Mechanisms to explain this
post-transcriptional regulation could include regulation of mRNA degradation pathways.
For example, both microRNAs and lncRNAs have been implicated in regulating mRNA
stability and degradation. miRNAs function as components of RNA-induced silencing
complexes (RISCs) by base pairing to mRNAs and either targeting them for degradation
or blocking their translation into protein (Filipowicz et al. 2008). In order for the changes
we are interested in to be detectable by microarray, they would have to involve the first
pathway: the mRNAs being targeted for degradation. Mechanisms for this effect include
the ability of the RISC complex to cause deadenylation or decapping of the transcript,
which ultimately leads to mRNA degradation by general machinery (Eulalio et al. 2008).
lncRNAs have also been shown to be involved in regulation of mRNA stability. They can
act as a miRNA “sink” by binding to it and blocking its ability to bind and degrade its
mRNA target (Mercer et al. 2009), or bind complementarily to the mRNA itself to
regulate its stability (Atianand and Fitzgerald 2014).
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Therefore, a possible mechanism for post-transcriptional regulation by rosi is the direct
regulation of miRNA or lncRNA transcripts by rosi treatment, which in turn would
regulate mRNA stability and degradation. We did not investigate whether miRNAs or
lncRNAs are regulated by rosi, though it is possible because at least one class of noncoding RNAs – eRNAs – are. In another model of NR-mediated transcriptional
regulation, estrogen treatment of breast cancer cells caused regulation of 37% of
annotated miRNA precursor transcripts (Hah et al. 2011) at early time points of
treatment. These mechanisms could be explored further to better understand regulation of
steady state mRNAs by secondary or non-transcriptional means.
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Figure 2.1 Rosiglitazone rapidly and robustly increases and represses gene
transcription in adipocytes.
Rosi regulation of RefSeq adipocyte gene transcription as measured by GRO-seq. GRO-seq
was performed on mature 3T3-L1 adipocytes treated for 0, 10m, 30m, 1h, or 3h with rosi. (A)
Increased transcription at the Fabp4 locus with rosi treatment. (B) The Rgs2 gene shows
repressed transcription upon rosi treatment. (C) Heatmap shows 1,951 genes that displayed a
significant change in transcription (FDR <.05) due to rosi treatment in at least one time point.
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Figure 2.2 Nascent gene transcript regulation by rosi correlates with regulation of
steady-state mRNAs.
Level of mRNA regulation (from microarray data) vs. gene body transcript regulation
(from GRO-seq) is plotted at each time point. The Pearson correlation coefficient is given
for each pair of time points.
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Figure 2.3 Some steady-state mRNAs may also be regulated on different timescales
or non-transcriptionally.
Levels of pre-mRNA and steady-state mRNA for several genes of interest as measured
by RT-PCR.
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Figure 2.4 Positive gene regulation by rosi is associated with number and proximity
of nearby PPAR sites.
(A) Distance from TSS to the nearest called PPAR site in genes that are up-regulated by
rosi, down-regulated by rosi, and unchanged.

p < 10-10 for up-regulated versus

unchanged genes by χ2 test. (B) Number of PPAR sites within 100kb of the TSS for the
three groups of genes. . p < 10-10 for up-regulated versus unchanged genes by χ2 test.
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Table 2.1 List of primers for gene expression
Name
Forward Sequence
Fabp4
CACTTTCCTTGTGGCAAAGC
mRNA
Fabp4
ATCGGGAATTTCAGCATGAC
premRNA
Pdk4
ATCATCTTTGGTGGCCGTAG
mRNA
Pdk4 pre- TAACTATGCCGTGCACCAAA
mRNA
Gyk
mRNA
Gyk premRNA
Acaa1b
mRNA
Acaa1b
premRNA
Arbp
mRNA

Reverse Sequence
AATGTGTGATGCCTTTGTGG
TCAAGCCCTGGTATTTCTGG

CATGGCTGCTCCTACAAACA
AAAGGCTCAAGGGGAAGAGA

CCCATCCTTCTCTTGGGAAT

GTACCAGCTCGACACGTTTTT

TGCTTGCTCACAGCTAGGAA

GAAGCATGGGCTTTTAGCAG

ATTCCCATGGTTCCCTCTCT

GCTGGTGGCATCAGAAATG

GCAGCAGTTCAGGGATTCTC

CCCAAACCCTTGACTGACAT

CCGATCTGCAGACACACACT

ACCCTGAAGTGCTCGACATC
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CHAPTER 3: The role and rosi-regulation of enhancers and eRNAs

Published in part in Genes & Development, 2014 May 1;28(9):1018-28.

The text, figures, and legends in this chapter were the work of Sonia Step with the
following exceptions. Jill Marinis performed the eRNA ablation experiments shown in
Figure 3.6. The C/EBP and C/EBP ChIP-seq experiments are the work of David
Steger, and the NCoR ChIP-seq was performed by Seo-Hee You. Hee-woong Lim
conducted the data processing and bioinformatics analyses.
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3.1 Introduction
PPAR binds at many thousands of sites in the genome (Lefterova et al. 2008; Nielsen et
al. 2008), yet it is difficult to determine which of these sites play an important role in
regulating gene transcription in response to rosi. Previous studies have relied on mapping
every PPAR binding site to its nearest gene to determine trends of regulation
(Haakonsson et al. 2013). These studies also showed that PPAR binding is largely
unaffected by rosi treatment, though occupancy at some sites is slightly increased. This
leaves the question of what causes rosi-dependent transcriptional changes.

There has been some evidence that changes in coactivator and corepressor occupancy
may be involved in rosi-mediated regulation. Early studies showed that rosi causes
dismissal of corepressors and recruitment of coactivators to individual sites in the
genome (Guan et al. 2005). More recently, a paper demonstrated that binding of the
coactivators MED1 and CBP is increased at PPAR sites near genes that are up-regulated
by rosi (Haakonsson et al. 2013). However, about half of rosi-regulated genes are actually
repressed rather than increased, and none of these studies contributed any insight into
rosi-mediated transcriptional repression.

eRNAs have garnered much interest in the last few years, as they have been shown to
contribute to transcription of their target gene (Lam et al. 2013; Li et al. 2013; Melo et al.
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2013). Additionally the production of eRNAs have been demonstrated to mark functional
enhancers, as measured by other markers of enhancers or by transcription of the nearest
gene (Hah et al. 2013; Zhu et al. 2013).

We use GRO-seq to identify thousands of bidirectional, intergenic eRNAs, detect those
that are regulated by rosi, and use these to categorize functional enhancers of rosimediated transcription. By focusing exclusively on these functional enhancers rather than
all PPAR sites, we examine the contributions of coactivator occupancy and other TFs to
transcriptional regulation. We find that rosi-upregulated eRNAs occur at sites of strong
PPAR binding to which coactivators such as MED1, CBP, and p300 are recruited.
Remarkably, however, downregulation of eRNA transcription occurs at sites that are
devoid of PPAR but enriched for C/EBP and AP-1 family members. MED1 and other
coactivators are dismissed at these downregulated sites, strongly supporting a mechanism
of negative regulation involving coactivator redistribution upon rosi binding to PPAR.

3.2 Materials and Methods
3.2a Cell culture
3T3-L1 cells were cultured as described in Chapter 2.
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3.2b GRO-seq library preparation
GRO-seq libraries were prepared as described in Chapter 2.

3.2c ChIP-qPCR and ChIP-seq
ChIP was performed as described previously (Steger et al. 2008). Cells were crosslinked
with 1% formaldehyde for 15 minutes, followed by quenching with 1/20th volume of
2.5M glycine and washed with 1x PBS. Cells were scraped down, transferred to a 1.5ml
tube, and pelleted by centrifugation for 5 minutes at 300g at 4°C. Cells were resuspended
in 1ml ChIP buffer (50mM Tris-HCl, 500mM NaCl, 1mM EDTA, 1% Triton X-100,
0.1% NaDOC, 0.1% SDS, and complete protease inhibitor tablet) and probe sonicated 3
times for 10 seconds at power 4, rested on ice, then probe sonicated 3 times for 10
seconds at power 6. Samples were centrifuged at maximum speed for 5 minutes at 4°C,
and the interlayer was removed to a fresh tube, avoiding the lipid top layer. This
clarification was repeated twice. Immunoprecipitation was performed at 4°C overnight
with the appropriate antibody, then bound to Sepharose A beads. Crosslinking was
reversed at 65°C overnight, then samples were digested with Proteinase K, and the DNA
was isolated using phenol/chloroform. Precipitated DNA was analyzed by qPCR. The
following antibodies were used in this study: C/EBP (sc-61x, Santa Cruz), C/EBP (sc150x, Santa Cruz), FOSL2 (sc-13017x, Santa Cruz), JUND (sc-74x, Santa Cruz), ATF2
(sc-6233x, Santa Cruz), MED1 (A300-793A, Bethyl), H3K27ac (ab4729, Abcam), CBP
(sc-369x, Santa Cruz), p300 (sc-585x, Santa Cruz), and NCoR (rabbit polyclonal,
generated in-lab). Primer sequences used for ChIP-qPCR are provided in Table 3.2. ChIP
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DNA was prepared for sequencing according to the amplification protocol provided by
Illumina. Next generation sequencing of ChIP-seq libraries were performed by the
Functional Genomics Core at the University of Pennsylvania, including preprocessing
and alignment of the raw tags.

3.2d eRNA expression
RNA isolation, reverse transcription, and qRT-PCR were performed as described in
Chapter 2. Primer sequences used to detect eRNA levels are listed in Table 3.1.

3.2e ChIP-seq data analysis
All the ChIP-seq tags for C/EBPα, FOSL2, ATF2, JUND, NCoR and MED1 were
aligned to mouse genome, mm8, using Bowtie with options, ‘-k 1 -m 1 --best –strata’,
and all the redundant tags were eliminated except one before downstream analysis. Peakcalling was performed using findPeaks command in Homer (Heinz et al. 2010). After
initial calling, all the peaks were resized to 200 bp, then 2 RPM cut-off was applied for
C/EBPα, FOSL2, ATF2, and JUND to select strong peaks and 1 RPM cut-off was applied
for MED1, CBP, p300 and NCoR because of their indirect genomic binding.
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3.2f FAIRE (Formaldehyde-Associated Isolation of Response Elements)
Cells were crosslinked as for ChIP, and nuclei were isolated by probe sonication. Nuclei
were sonicated in the Bioruptor (7.5 minutes on medium, 30 seconds on/30 seconds off).
Samples were spun for 10 minutes at maximum speed, then lysates were pooled. An
aliquot was removed for input, then lysates were extracted 3 times with
phenol/chloroform in PhaseLock tubes. The aqueous phase was removed, and incubated
at 65°C overnight. Samples were digested with Proteinase K, and then DNA was
precipitated as during ChIP and analyzed by qPCR. Primer sequences are listed in Table
3.2.

3.2g Transfection
For ablation of eRNA by siRNA, antisense oligo (ASO), and locked nucleic acid (LNA),
mature differentiated 3T3-L1 adipocytes were electroporated using Amaxa Cell Line L
(program A-033, Lonza). One quarter of a 10-cm dish of cells was treated with 200 pmol
of ASO or LNA, or 350 or 700pmol siRNA as indicated (sequences in Table 3.3) and
plated onto one well of a 12-well dish. Cells were harvested 24-30h post-transfection and
RNA was isolated.

3.2h eRNA analysis
For eRNA analysis, we defined an enhancer as an intergenic center of a bidirectional
transcript. After pooling both replicates to improve transcript coverage for each time
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point, we identified all the putative transcripts in plus and minus strands using the
findPeaks command in Homer. Two start sites of a plus transcript and a minus transcript
were paired together if their distance is less than 1kb, and then their midpoint was defined
as a center of a bidirectional transcript. Any of these centers were discarded if they are
located within 2kb from RefSeq genes or Satellite regions to avoid potential bias from
gene body transcripts or abundant signal from Satellite regions. To investigate rosiinduced eRNA regulation, we used a similar pipeline as the gene transcript analysis
described in Chapter 2, with the following differences. When counting tags for eRNA, we
considered 2kb window only around the previously defined enhancer and summed plus
and minus tags. Coverage cut-off was not applied, but the 0.5RPKM cut-off was still
applied. Among eRNAs that passed the cut-off, those with FDR < 0.05 was considered
rosi-regulated and the others were considered non-regulated. For the clustering analysis,
we used log2(fold-change over untreated) in each time point and Euclidean distance.
Initial dendrogram was created by Ward’s criterion then further subjected to optimal leaf
ordering. De novo motif search was performed using HOMER more than once for a
given set of genomic loci, and the consensus motifs were considered for downstream
analysis only if they appear consistently with significant p-value.
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3.3 Results
3.3a Adipocyte eRNAs are regulated by rosi treatment and correlated with regulation of
the nearest gene.
In addition to gene body transcription, GRO-seq revealed robust bidirectional transcripts
at enhancers, or eRNAs (Core et al. 2008; Kim et al. 2010), which were identified and
quantified in an unbiased, genome-wide analysis (Figure 3.1). For example, bidirectional
eRNAs were identified at enhancers upstream of the Fabp4 locus, and their transcription
was observed to be upregulated by rosi (Figure 3.2A). Indeed, unbiased de novo calling
of bidirectional intergenic transcripts confirmed that the transcription of many eRNAs
was strongly and rapidly regulated by rosi, and downregulated eRNAs greatly
outnumbered upregulated eRNAs (Figure 3.2B). This was similar to the effect of rosi on
gene body transcription and, as has been observed in other systems (De Santa et al. 2010;
Kim et al. 2010), the effect of rosi on eRNA transcription correlated strongly with
transcription at the nearby gene bodies (Figure 3.3). The correlation was confirmed at
eRNA/gene body pairs by qPCR, which also demonstrated that eRNA induction often
preceded gene induction (Figure 3.4A). The correlation was validated at repressed
eRNA/gene pairs as well (Figure 3.4B). Though intragenic eRNAs were excluded from
downstream analysis because of difficulties in identifying them reliably, we observed that
many follow a similar pattern of correlation with the target gene (Figure 3.5).
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3.3b Ablation of eRNA transcripts has no effect on transcription of nearby genes.
To test whether the eRNA transcript has a functional role in increasing gene transcription,
we ablated eRNAs using several methods and tested levels of the eRNA, its target gene,
and a distant non-target gene as a control using qRT-PCR. Targeting an eRNA near the
Tusc5 gene (a relatively well-conserved eRNA) for degradation using an antisense
oligonucleotide (ASO) led to robust suppression of eRNA levels, but no statistically
significant effect on Tusc5 mRNA (Figure 3.6A). Similarly, targeting an eRNA upstream
of Fabp4 for degradation by locked nucleic acid (LNA) gapmers resulted in a large
decrease in eRNA levels, and though a small decrease was measured in Fabp4 mRNA,
this decrease was seen in off-target genes as well, such as Pparg2 (Figure 3.6B). Using
siRNA to ablate the same Fabp4 eRNA had some minor effects on Fabp4 mRNA at
higher concentrations, but again off-target effects were seen at the Pparg2 gene as well
(Figure 3.6C).

3.3c Down-regulated eRNAs are devoid of PPAR and are enriched for several C/EBP
and AP-1 factors.
Since rosi is known to positively regulate PPAR activity and transcription of its target
genes, we investigated the differential regulation of eRNAs by PPAR and other
transcription factors. Indeed, upregulated eRNAs were extremely likely to have PPAR
bound nearby (85%), much more so than unregulated or downregulated eRNAs (Figure
3.7A). In fact, downregulated eRNAs were relatively devoid of PPAR binding, as will
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be discussed below. Furthermore, strong PPAR binding as measured by total normalized
tag counts from ChIP-seq was enriched at upregulated eRNAs, but not at downregulated
eRNAs, relative to unregulated eRNAs (Figure 3.7B). PPAR binding sites that overlap
with eRNAs had higher PPAR occupancy than those that lack eRNAs, further
suggesting that enhancers with eRNAs are more likely to be functional (Figure 3.7C).

In contrast to the upregulation of transcription by rosi, PPAR strength of binding was
not enriched at rosi-repressed eRNAs. Though 23.6% of downregulated eRNAs had
PPAR bound (Figure 3.7A), this percent was far less than at unregulated eRNAs, and
the binding tended to be extremely weak (Figure 3.7B). Moreover, unlike upregulated
genes, the number, strength, and proximity of PPAR binding were not enriched near the
TSS of downregulated genes relative to unchanged genes (Figures 2.4A, 2.4B). Together
these data strongly suggest that PPAR does not mediate the repression of eRNA and
gene body transcription by rosi directly, i.e., by binding in cis with the regulated gene
body, as was the case at the majority of rosi-upregulated eRNAs.

To investigate which transcription factors may be involved in rosi-mediated
transcriptional repression, we performed motif analysis at sites containing regulated
eRNAs. Consistent with enrichment of PPAR at upregulated eRNAs, de novo motif
finding analysis at sites of rosi-induced eRNAs revealed strong enrichment for a
sequence that is highly similar to the canonical PPAR/RXR binding site (Figure 3.8A).
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In contrast, de novo motif analysis of sites with downregulated eRNAs produced two
highly enriched motifs that most resembled a C/EBP:AP-1 hybrid motif and the canonical
AP-1 motif (Figure 3.8B). ChIP-seq analysis for C/EBP and AP-1 factors that are
abundant in adipocytes revealed significant enrichment at downregulated eRNAs of
C/EBP, C/EBP, FOSL2, JUND, and ATF2. (Figure 3.9A). A higher percentage of
downregulated eRNAs, compared to upregulated and nonregulated, had these C/EBP and
AP-1 factors bound (Figure 3.9B). Interestingly, although C/EBP has been shown to be
enriched near genes repressed after rosi treatment (Vernochet et al. 2009; Haakonsson et
al. 2013), in our data the enrichment was higher for other factors, including FOSL2 and
JUND (Figure 3.9). The finding that both C/EBP factors and all three AP-1 factors are
enriched at downregulated sites suggests that each of these factors, potentially along with
other TFs but notably not PPAR, is located at eRNAs in cis with gene bodies whose
transcription is negatively regulated by rosi and may be involved in transcriptional
repression.

3.3d Rosi-mediated transcriptional repression may be mediated in part by redistribution
of coactivators.
The strength of C/EBP and AP-1 binding did not change upon rosi treatment (Figure
3.10), suggesting that it was not a change in TF occupancy that was driving rosi-mediated
transcriptional repression. Instead, we hypothesized that the repression could be related to
coactivator redistribution to the rosi-bound PPAR. ChIP-seq for the general coactivator
MED1 was performed in the presence and absence of rosi. We then determined the sites
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of MED1 occupancy that contained eRNAs, and whether these eRNAs were up- or
downregulated by rosi. As expected, MED1 recruitment to sites of PPAR binding at
upregulated eRNAs was increased by rosi (Figure 3.11A).

Remarkably, 1h of rosi treatment decreased MED1 recruitment at sites of downregulated
eRNA transcription despite the general absence of PPAR at these sites (Figure 3.11B).
These results were confirmed at several representative sites of up- and downregulated
eRNAs by MED1 ChIP-qPCR (Figure 3.11C). On average, upon rosi treatment MED1
recruitment significantly decreased at downregulated eRNAs and increased at
upregulated eRNAs relative to unregulated eRNAs (Figure 3.11D). Furthermore,
redistribution of a coactivator to upregulated sites and away from repressed sites was not
limited to only MED1. ChIP-seq for the coactivators CREB-binding protein (CBP) and
p300 in the presence and absence of rosi showed a modest but consistent and statistically
significant redistribution upon rosi treatment similar to MED1 (Figures 3.12A, 3.12B).
Notably, occupancy of the corepressor NCoR was not altered upon rosi treatment (Figure
3.12C), suggesting that transcriptional repression may be driven by redistribution of
coactivators, rather than replacement of coactivators with corepressors. Surprisingly, we
did not observe significant changes in H3K27ac or chromatin accessibility by FAIRE at
sites of eRNAs regulated after 1h of rosi treatment, although we cannot rule out changes
in chromatin marks at later time points (Figure 3.13).
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3.4 Conclusions
eRNAs are of great interest, as they have been shown to contribute to enhancer function
and influence transcription at the target gene body (Kaikkonen et al. 2013; Lam et al.
2013; Li et al. 2013; Melo et al. 2013). However, we found no effect of eRNA ablation –
whether by siRNA, LNA, or ASO – on transcription of nearby genes. This suggests that
at least not all eRNAs have a functional role in promoting gene transcription. It is
possible that those that resemble long non-coding eRNAs more closely – longer,
unidirectional, poly-A tailed, etc – are more likely to play a functional role in
transcription.

We were able to detect adipocyte eRNAs, on a genome-wide level, and quantification of
their basal and rosi-regulated rates of transcription revealed a high correlation between
eRNA transcription and transcription at the nearby genes. At rosi-upregulated eRNAs,
PPAR binding was highly enriched and was actually required for eRNA transcription.
Upregulation of gene body transcription by rosi was correlated with recruitment of the
coactivators MED1, CBP, and p300 to the site of eRNA transcription, in agreement with
a recent study that found MED1 was recruited to PPAR binding sites (Haakonsson et al.
2013). Thus, activation of gene transcription by rosi fits a general model of NR function
in which ligand binding facilitates the recruitment of coactivators to PPAR bound in cis
with a regulated gene body. The site of PPAR binding functions as an enhancer,
generating eRNAs that correlate with the level of gene body transcription. The effect is
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greatest when multiple strong PPAR binding events occur in relatively close proximity
to the TSS.

In contrast, rosi-downregulated eRNAs are quite different. They are depleted of PPAR
binding compared to background levels, but are enriched for other TFs, especially
members of the C/EBP and AP-1 TF families. Nevertheless, despite the fact that PPAR
is not bound in the vicinity, rosi treatment leads to dismissal of the coactivators from
these sites. This suggests that a primary mechanism of rosi-dependent transcriptional
repression involves squelching of essential coactivators from enhancers lacking PPAR.
Consistent with this, the induction of the PPAR-dependent, rosi-induced eRNAs
preceded the downregulation of non-PPAR-dependent eRNAs.

In contrast to upregulated enhancers, which depend upon activation of PPAR and
recruitment of coactivators such as MED1, downregulated sites where MED1 binding
was lost were enriched for TFs other than PPAR. This suggests that, in principle, any TF
driving transcription at a PPAR-independent enhancer would be susceptible to the
repressive effects of rosi redistributing coactivators to PPAR. Indeed, this may explain
why the downregulated enhancers are enriched for binding of multiple factors, including
C/EBP, C/EBP, FOSL2, ATF2, and JUND. Of these, only C/EBP has previously
been implicated in rosi-mediated transcriptional repression (Vernochet et al. 2009;
Haakonsson et al. 2013), and notably, in our studies C/EBP was less enriched at
downregulated sites relative to the AP-1 TFs.
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A role for coactivator redistribution, or squelching, has been previously suggested to
explain transcriptional repression by NRs, but most of those studies were performed
using transfection to overexpress receptors or coactivators, and used reporter genes as
readouts (Kamei et al. 1996; Fronsdal et al. 1998; Lee et al. 2000; Li et al. 2000; Kim et
al. 2001; Zhang and Teng 2001; Manna and Stocco 2007; He et al. 2012; Pascual-Garcia
et al. 2013). This model gained further support recently with evidence that the
endogenous coactivator NCOA3 is lost from sites of diminished DNase I hypersensitivity
upon E2 hormone treatment in MCF-7 cells (He et al. 2012). Here our analysis of eRNAs
has allowed us to focus on regulated enhancers and interrogate this mechanism in the
context of the endogenous genome and TFs in adipocytes, where the only manipulation
was treatment with the PPAR ligand, and to link the coactivator redistribution to
changes in transcriptional levels of both eRNAs and genes.

We found five C/EBP and AP-1 transcription factors enriched at down-regulated eRNAs,
and the coactivator redistribution mechanism we propose suggests that any transcription
factor other than PPAR could lose its coactivators and drive transcriptional repression
upon rosi treatment. Further studies should investigate whether all of these transcription
factors, and others, indeed play an equal role in transcriptional down-regulation.
Furthermore, the fact that eRNA regulation correlates so highly with regulation of the
target gene may be evidence of a physical interaction between enhancer and promoter,
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such as a chromatin loop. Studies such as chromatin conformation capture (3C) could
determine whether the strength of looping is altered at sites with regulated eRNAs.

The strength of our approach lies in using regulated eRNAs to identify functional
enhancers, which allows unbiased, de novo detection of novel important factors. In fact,
our lab has recently used a very similar approach to identify enhancers and factors that
drive circadian transcription in the liver (Fang et al. 2014). These methods could be
extended to many other systems and questions.
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Figure 3.1 eRNAs are transcribed in adipocytes.
Genome-wide average signal of intergenic bidirectional transcripts in untreated
adipocytes from the plus and minus strands.
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Figure 3.2 Adipocyte eRNAs are regulated by rosi.
(A) Two bidirectional eRNAs are transcribed at enhancers upstream of the Fabp4 TSS
and up-regulated by rosi treatment. eRNA centers are indicated by arrows. (B) Heatmap
showing all rosi-regulated eRNAs found in an unbiased manner (N=2251).

59

Figure 3.3 eRNA regulation and gene regulation are correlated on a genome-wide
level.
Correlation between rosi-regulated eRNAs and the regulation of the nearby gene for all
pairs of matching time points (N=462). For each gene, eRNAs within 100kb of the TSS
were included in the analysis.
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Figure 3.4 Examples of correlation between eRNA and gene regulation.
(A) Correlation between gene and eRNA rosi regulation as measured by RT-qPCR for
four example genes: Fabp4, Pdk4, Acaa1b, and Ppargc1b. N=3; error bars indicate SEM.
(B) Repression at regulated eRNAs and nearby genes is confirmed by RT-qPCR for three
example genes: Angpt1, Jun, and Nr1d1. N=3; error bars indicate SEM.
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Figure 3.5 Examples of intragenic eRNAs that correlate with gene regulation.
(A) Screenshot of the Angptl4 gene locus. Approximate eRNA center is indicated by the
arrow. (B) Screenshot of the Pparg gene locus. Approximate eRNA center is indicated by
the arrow.
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Figure 3.6 Ablation of individual eRNAs has no effect on transcription of the nearest
gene.
(A) qRT-PCR for the eRNA near Tusc5, Tusc5 mRNA, and Pparg2 mRNA as a control
after ablation of the eRNA with an antisense oligonucleotide. (B) qRT-PCR for the eRNA
upstream of Fabp4, Fabp4 mRNA, and Pparg2 mRNA after ablation of the eRNA with
locked nucleic acid (LNA) gapmers. (C) qRT-PCR for the eRNA upstream of Fabp4,
Fabp4 mRNA, and Pparg2 mRNA after ablation of the eRNA with siRNA.
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Figure 3.7 Rosi-up-regulated eRNAs are enriched for PPAR binding, but downregulated ones are depleted of it.
(A) Percentage of up-regulated, down-regulated, and unregulated eRNA sites that overlap
with a called PPAR peak from ChIP-seq. (B) Total PPAR tag count, in reads per
million (RPM), within 1kb of up-regulated, down-regulated, and unregulated eRNA sites.
(*) p = 7.7 x 10-95 versus unregulated sites; (**) p = 1.8 x 10-20 versus unregulated sites.
(C) Occupancy of PPAR in RPM is plotted at sites that contain or do not contain an
eRNA.
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Figure 3.8 Up- and down-regulated eRNAs are enriched for different motifs.
(A) Top hit from HOMER de novo motif search at up-regulated eRNAs. The closest
known motif, the DR1 motif, is shown for reference. The enrichment for this motif was
45% at the target sites and 13.5% in the background sites. (B) Top two hits from HOMER
de novo motif search at down-regulated eRNAs. The closest known motif for each is
shown for reference.
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Figure 3.9 Down-regulated eRNAs are enriched for binding of C/EBP, C/EBP,
FOSL2, JUND, and ATF2.
(A) Total tag counts in reads per million (RPM) within 1kb of the center of the regulated
eRNAs from ChIP-seq for the following factors: C/EBP, C/EBP, FOSL2, JUND, and
ATF2. (*) p < 4.6 x 10-5. (**) p < 10-10. (B) Percentage of regulated eRNAs that overlap
with called peaks of C/EBP, C/EBP, FOSL2, JUND, and ATF2.
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Figure 3.10 Strength of binding of C/EBP and AP-1 factors does not change upon
rosi treatment.
ChIP-qPCR at several strong binding sites for C/EBP, C/EBP, FOSL2, JUND, and
ATF2 before and after 1h of rosi treatment. Primer sequences are listed in Table 3.2.
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Figure 3.11 MED1 binding is increased upon rosi treatment at up-regulated eRNA
sites and decreased at down-regulated sites.
(A) Scatter plot comparing MED1 binding strength in reads per million (RPM) with and
without 1h of rosi treatment, with sites containing an up-regulated eRNA highlighted in red.
(B) Scatter plot comparing MED1 binding strength with and without 1h of rosi treatment,
with sites containing a down-regulated eRNA highlighted in blue. (C) MED1 ChIP-qPCR at
sites with up-regulated or down-regulated eRNAs. N = 5. Error bars indicate SEM. (*) p <
0.05; (**) p < 0.01; (***) p < 0.005 by paired t-test. (D) Box plot showing average log2 of
fold change in MED1 occupancy upon rosi treatment at sites of regulated eRNAs. (**) p <
10-15.
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Figure 3.12 The coactivators CBP and P300 are also redistributed upon rosi
treatment, but the corepressor NCoR is not.
(A) Box plot showing average log2 of fold change in CBP occupancy at up-regulated,
down-regulated, and unregulated eRNA sites. (**) p < 10-15. (B) Box plot showing
average log2 of fold change in P300 occupancy at up-regulated, down-regulated, and
unregulated eRNA sites. (**) p < 10-15. (C) Box plot showing average log2 of fold change
in NCoR occupancy at up-regulated, down-regulated, and unregulated eRNA sites. N.S. =
not statistically significant.
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Figure 3.13 Rosi does not cause changes in levels of H3K27ac or open chromatin as
measured by FAIRE.
(A) ChIP-qPCR for H3K27ac at enriched sites before and after 1h of rosi treatment.
Primers sequences are listed in Table 3.2. (B) FAIRE-qPCR at several regulated sites
before and after 1h of rosi treatment. Primer sequences are listed in Table 3.2.
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Table 3.1 List of primers for eRNA and gene expression
Name
Fabp4
premRNA
Fabp4
eRNA
Pdk4 premRNA
Pdk4
eRNA
Acaa1b
premRNA
Acaa1b
eRNA
Ppargc1b
premRNA
Ppargc1b
eRNA
Angpt1
premRNA
Angpt1
eRNA
Jun
premRNA
Jun
eRNA
Nr1d1
premRNA
Nr1d1
eRNA
Tusc5
eRNA 2
Tusc5
Fabp4
eRNA
Fabp4

Forward Sequence
ATCGGGAATTTCAGCATGAC

Reverse Sequence
AATGTGTGATGCCTTTGTGG

TGAGTCCCCCACTTGCTTTA

CACCCTGTAAGGCTGGTGAT

TAACTATGCCGTGCACCAAA

AAAGGCTCAAGGGGAAGAGA

TTAACAAAGAAAACAGGCAA CATCAGTACCCTCAAAACACAA
CA
A
GCAGCAGTTCAGGGATTCTC CCCAAACCCTTGACTGACAT

ACAGCAGGTGTGGTGACTTG

TGCATCCTTGAGGAACAAGA

TGAATGCACAGTGGTTTGGT

TGTACCCGCCACACAAGTAA

TCTATTGTTAGGCTGTGAAA
CATT
ACGATGTAAGTCCGGCAGAA

TATGCATCCCCAGTCCTCAT

CCATTTACAGCCAACGGTCT

CCAAACTATTTGCTCCTGGTG

GGTCCCTGCTTTGAGAATCA

GCAGACACTTTGGTTGAAAGC

GAAGTTGAGCGGGTTTGAGA

TTCCAGGTACAGCACACTGC

AGGCAGGGCAACCTTAAAAT

TGAAACCATAGCCGGGTAAC

CAGAAGATTCTCCTCCCGTA
AA
TTCAAAACAAAACCCCCTTT

AGAGCATCCAAGCCTGACAA

CCCCTGCTGCACACTACTTC
GGAAACCCACACAAGCTGTT

TTACCTGGTCCTTGCCATTG
GGGCATGGCATACAGAAACT

CACTTTCCTTGTGGCAAAGC

AATGTGTGATGCCTTTGTGG
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TGCTTTAAGCGTACAACCAAAA

GAATTATTCCCCGTGATCCA

Pparg2
Arbp

TGGGTGAAACTCTGGGAGAT
TC
CCGATCTGCAGACACACACT

GAGAGGTCCACAGAGCTGATTC
C
ACCCTGAAGTGCTCGACATC

Table 3.2 List of primers for ChIP-qPCR and FAIRE-qPCR
Name
C/EBP up1
C/EBP up2
C/EBP up4
C/EBP up5
C/EBP down2
C/EBP down3
C/EBP down4
C/EBP down6
ATF2 site 1
ATF2 site 2
ATF2 site 3
ATF2 site 4
ATF2 site 5
FOSL2/JUND
site 1
FOSL2/JUND
site 2
FOSL2/JUND
site 3
FOSL2/JUND
site 4
FOSL2/JUND
site 5
Fabp4 site 1

Forward Sequence
AGCCAGGGAATCTGCTTAG
G
TGTCACAACTACTAACCCT
GTTGA
GCCTCTCGAAATGTTTGTC
C
CTGTACCTTTTTGGCCTTGG
GGCCAAATCAGTTCCTGAA
A
GGGCTTGGAGACTGTAGCT
G
CTCAGTTGCTCCCTTTCACC
AGCGCAGACTCCCTCTAAT
G
CATCAGGAAGTTGGCCTCT
G
CGAACTCCAGGGATTTTCT
G
GGACAGCGGAGTTCTCTAG
C
CGCGTCTTGATTGGTCACT
TCATCCTGTGAGCCTGATT
G
GGAAAAGCCACACCCTACA
A
GCCAGAGCATGGGTTTTCT
A
AGCTACCAAGTGACTGCCA
AG
GACTCATTTCCCAGCTGAC
C
ATGATGCAATTGGGCTCCT

Reverse Sequence
TGGCATTGCATGTTATTGCT

AATGTCAGGCATCTGGGAA

GACAAAGGCAGAAATGCACA
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TGTCCCCATGACAACTAATGA
GCCAGACAGAATGGAAGCA
CTCACATGCTGGAAACCTCA
GTTGTGGGGAGTGAAGCAAT
CTCTGGCTCCTTGAGCAATC
GGCAACTCTTTTCCCTCCTC
CAACGGTTTCAAAACCCAGA
GGCTTTCCTCTGCTTCTCCT
GCAAACCGTGGTCCTTTCTA
TGAGAATAGCATGCAGTGTGC
AGGCAGGTGTCCTGGTCTC
CATCCCACATTCATCCACTG
GGGACTTTCTTCAGGAGCCTA
TTGGACAGGCCATGTGACTA
TTGAGCAGCGTGATGAAATC
CAATTCAAAAGGGGAACTCG
CTGACTGTGCTGGCTGACTC

C
Fabp4 site 2
GTGGAAGCTGAAGCTGCTG
T
MED1 site 1
CCCCACTGTTGCAAAAATC
T
MED1 site 2
TTAAAAGAACGAGCCCCAA
A
MED1/H3K27 AATGGTTGGAGGCCAGTAA
site 3
A
MED1/H3K27 TTTCCCCAGGAAAGTTCAG
site 4
A
MED1 site 5
GCATTTCTCAGCCAGGAGT
C
MED1/H3K27 GCACTATTGCGTTCCCTTTC
site 6
Pparg-122k
AGCTTTGCTGGCTAGAGGT
G
Angptl4 PPRE CTGAAACTGCATGCCTCAA
G
Pdk4 PPRE
AGAGTTCTCTGGGGGAAAG
G
Arbp
TCATCCAGCAGCAGGTGTT
TGACA
Ins
TGCTTGCTGATGGTTTTTGA

GTCCCTGGGAATGATTTGTG
CCCTGGCCTACAAGAGCTTA
AATGGCTTGCAAAACTCCAC
AGTTGGAAGCGTTCATTGCT
CCCTGAGATGAGGTTGGTTG
GGCACAGAGGAAGCTCAGTC
TGGCTAGGTCCAAGGACAAC
TTTCGCAGAACTGAGGTTGA
TTCCTGTCTGCCTGTCACTG
CCACTTGGGCAACAGAATTT
GGCACCGAGGCAACAGTT
CAGAGAGGAGGTGCTTTGGT

Table 3.3 List of sequences for ASO, LNA, and siRNA
Name
asNTC
as Tusc5 PPRE1 eRNA
as Tusc5 PPRE2 eRNA
LNA gapmer1
LNA gapmer 2
NTC si
Fabp4 eRNA si1
Fabp4 eRNA si2

Sequence
TAGCGACTAAACACATCA
GTTATCTCTCCAGTGCCCA
GCATTCGTCTCCAGGCTTT
ATCAGGCCACCACTATGTA
TGCTTTCAGAAACGGGAACT
UAGCGACUAAACACAUCA
AUGGCAUACAGAAACUGCCCCUUGAGCAGUUUCUU
AAAUUUGUUAUUGGCAGAAAGUCCCUCUGCCAAUA
A
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CHAPTER 4: Regulation of adipocyte transcription by MRL-24
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4.1 Introduction
Alternative mechanisms have been suggested to explain the dysregulation of PPAR
signaling in obesity or diabetes and subsequent improvement by TZD treatment. In one
such model, PPAR is phosphorylated at Ser273 by Cdk5. This phosphorylation is
increased in adipose tissue by high fat diet or pro-inflammatory treatments such as
TNF, but blocked by TZDs (Choi et al. 2010). The phosphorylation is also effectively
blocked by a compound called MRL-24, which binds to PPAR and improves glucose
tolerance but lacks agonist activity in a PPAR transactivation assay. In both the adipose
tissue of MRL-24-treated mice and in a cell culture model of differentiated fibroblasts
treated with MRL-24, the compound did not activate the majority of expected PPAR
target genes that are up-regulated with rosi, but instead up-regulated a unique subset of
target genes. Understanding these differentially regulated gene targets may be critical to
dissociating the positive anti-diabetic effects of these drugs from the adverse effects.

The same group followed up this work with another paper in which they created other
novel synthetic compounds that bind to PPAR and block its Cdk5-mediated
phosphorylation, but lack classical transcriptional agonism (Choi et al. 2011). They
showed that one such compound, SR1664, had potent anti-diabetic activity in vivo
without causing some of the adverse effects that plague TZDs, including weight gain,
fluid retention, and inhibiting bone formation in culture. A separate group developed
another compound, called GQ-16, that retains similar insulin-sensitizing effects to rosi
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without causing weight gain or edema (Amato et al. 2012). It acts as a partial PPAR
agonist in transactivation and adipogenesis studies and inhibits Cdk5-mediated
phosphorylation of PPAR in vivo. Hydrogen/deuterium exchange studies and molecular
dynamics modeling suggest that GQ-16 binds differently than rosi, and is less effective at
stabilizing helix 12 in its active conformation. Lastly, a compound called INT131 was
shown clinically to improve blood glucose in diabetic patients without associated weight
gain or fluid retention (DePaoli et al. 2014). This is discussed in more detail in Section
5.2d.

These studies still leave many questions unanswered about the mechanistic link between
phosphorylation of PPAR and its transcriptional activity. This mechanism may still
involve regulated recruitment of coregulators, similar to the way rosi functions as
described in Chapter 3. We sought to further explore the regulation of transcription by
MRL-24, with the eventual goal of using MRL-24-regulated eRNAs to identify whether
it functions by regulating the same group of enhancers as rosi or distinct ones, and
whether the altered phosphorylation of PPAR causes differential recruitment of
coactivators to drive transcriptional changes. However, we find that in the 3T3-L1 model
of adipocytes, MRL-24 does not up-regulate the previously described unique set of target
genes distinct from rosi. Instead, its function resembles that of a partial agonist: it
regulates many of the same targets as rosi, but less robustly.
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4.2 Materials and Methods
4.2a Cell culture
Cells were cultured as described in Chapter 2, and treated with 1M rosiglitazone
(Biomol) or 1M MRL-24 (Merck) when stated.

4.2b Gene expression analysis
RNA was isolated from cells and analyzed by microarray or qRT-PCR as described in
Chapter 2. Primer sequences used for qPCR are listed in Table 4.1.

4.3 Results
4.3a Previously identified MRL-24-specific gene targets are not differentially regulated
in our model.
MRL-24 was previously demonstrated to selectively increase transcription of a subset of
PPAR target genes (Choi et al. 2010). To test these findings in our model, adipocytes
were treated for 24h with 1M rosi or MRL-24, and then gene expression levels of the
putative MRL-24-specific genes were tested by qRT-PCR. Unexpectedly, none of these
genes were robustly increased by MRL-24 (Figure 4.1). To confirm that the treatments
worked, and to investigate whether MRL-24 is able to agonize classical PPAR target
genes similar to rosi, qRT-PCR was performed with gene expression primers to known
rosi target genes. MRL-24 increased expression of these genes to a comparable level as
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did rosi (Figure 4.2), suggesting that both drugs were active and had many of the same
transcriptional effects.

4.3b Microarray comparing effects of MRL-24 and rosi does not identify any MRL-24specific target genes.
To further investigate whether there were any gene targets specific to MRL-24 and not
rosi, microarray was performed on untreated adipocytes as well as those treated with
1M rosi or MRL-24 for 24h (Figure 4.3). Each point represents a gene regulated by at
least one drug, with fold-change over the untreated control plotted for rosi on the x-axis
and for MRL-24 on the y-axis. The very high correlation between the two treatments (r =
0.79) suggests that on a genome-wide level, the two drugs regulate most of the same gene
targets. The relatively low slope of 0.47 suggests that while MRL-24 targets many of the
same genes as rosi, it up-regulates them to lower degree, similar to a partial agonist.

To further test whether any of the genes that fall above the best-fit line may in fact be
robust MRL-24-specific targets, the samples were tested by qRT-PCR with primers to
those genes. When performed on the same cDNA samples as used for the microarray,
qRT-PCR confirmed MRL-24-specific regulation (Figure 4.4A), but when repeated in an
independent experiment the result was not replicated (Figure 4.4B), suggesting that the
MRL-24-specific regulation was an artifact of the original experiment, and no robustly
MRL-24-specific genes could be found by microarray.
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Since the results in Chapter 3 support the idea that eRNA regulation can provide valuable
insight into which enhancers are regulated by a TF ligand, we examined whether MRL24 regulates any eRNAs differently than rosi, and whether this could provide any
information about its mechanism. Very preliminary evidence suggests that while rosi upregulates eRNAs associated with its target genes (such as Pdk4 and Fabp4), MRL-24 may
not be regulating these eRNAs (Figure 4.5) despite regulating the same target genes
(Figure 4.2).

4.4 Conclusions
Much attention has been devoted to the development and study of selective PPAR
modulators, or SPPARMs, with the hope that we may be able to dissociate the positive
metabolic effects of TZDs from their adverse effects. MRL-24 has been shown to
regulate only a selective subset of PPAR target genes, and this was thought to explain its
favorable risk/benefit profile. We were unable to confirm any of its unique target genes,
though this could be due in part to different cell culture models. The experiments we
performed were all done in the 3T3-L1 cell culture model of adipocytes. In contrast, the
published studies on MRL-24 were performed either in vivo, in which mice were treated
with MRL-24 and then their white adipose tissue was harvested and studied, or in vitro
but in a different cell culture model (Choi et al. 2010). Their gene expression studies
were performed in a cell culture model in which mouse embryonic fibroblasts from
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PPAR-null mice were cultured, FLAG-PPAR was retrovirally overexpressed, cells
were selected, and the cells were differentiated into adipocytes with the hormonal
cocktail of dexamethasone, insulin, and isobutylmethylxanthine. Clearly this cell culture
model is considerably different from the model of 3T3-L1 adipocytes, and it is thus not
surprising that many genes may be regulated differently in the two models. What is
surprising, however, is that MRL-24, which was shown to selectively regulate a group of
genes in differentiated MEFs, did not uniquely regulate any genes at all in our model. Not
only were we unable to identify any robustly selective MRL-24 gene targets, but the drug
behaved very similar to a partial agonist, regulating most of the same genes as rosi but to
a lesser extent.

Despite the lack of MRL-24 specific genes, the drug could still be functioning through a
different mechanism than rosi. GRO-seq on MRL-24-treated cells followed by
identification of regulated eRNAs could identify differentially regulated or selective
enhancers. We could not identify any MRL-24-specific genes, though this could be in
part due to our model, 3T3-L1 cells, which may not adequately reflect the behavior of
adipocytes in vivo. Nevertheless, this preliminary data suggests that MRL-24 may not
truly be a selective enough ligand to dissociate favorable physiologic effects from
adverse ones.
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We could not confirm any unique target genes for MRL-24, or find any evidence that it
behaves as a SPPARM. Nevertheless, there are other SPPARMs currently being studied
or in clinical development that hold more promise. For example, a compound called
INT131 has shown promise in early clinical studies for improvement of blood glucose
without the associated toxicities of TZDs (DePaoli et al. 2014), and biochemical studies
suggest that it functions as a SPPARM. Studies investigating how this compound and
others regulate transcription using GRO-seq and ChIP-seq could shed more light on their
mechanisms of action, including which functional enhancers they regulate and whether
they drive transcriptional changes through the redistribution of coactivators. This is
discussed in more detail in Section 5.2d.
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Figure 4.1 Previously defined MRL-24-specific genes are not specific targets in this
model.
mRNA levels of genes previously identified as selectively up-regulated by MRL-24 but
not rosi were measured by qRT-PCR in control adipocytes and adipocytes treated for 24h
with rosi or MRL-24.
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Figure 4.2 Most classic adipogenic PPAR target genes are regulated by MRL-24 to
comparable levels as by rosi.
Levels of classic PPAR target genes were measured by qRT-PCR in adipocytes and
adipocytes treated for 24h with rosi or MRL-24.
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Figure 4.3 MRL-24 regulates most of the same gene targets as rosi on a genomewide level.
Scatterplot representing mRNA regulation in adipocytes treated for 24h with rosi or
MRL-24 over control as measured by microarray. The slope of the best-fit line is 0.47.
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Figure 4.4 Potential MRL-24-specific genes from microarray are artifacts of the
experiment.
(A) qRT-PCR for several genes determined to be MRL-24-specific from the microarray
in Figure 4.3 in the same RNA samples used for the microarray. Fabp4 was used as a
control. (B) qRT-PCR for the same genes in an independent experiment of adipocytes
treated for 24h with rosi MRL-24. (*) p < 0.05; (**) p < 0.01; (***) p < 0.005.
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Figure 4.5 Preliminary evidence suggests that enhancers may be differentially
regulated by MRL-24.
qRT-PCR for mRNAs (mPdk4, mFabp4), pre-mRNAs (gPdk4, gFabp4, gAntpl4) and
nearby eRNAs in adipocytes treated for 24h with rosi or MRL-24.
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Table 4.1 List of primers for eRNA and gene expression
Name
Chemerin
Nr3c1
Txnip
Adipsin
Arhgap23
Itgav
Usp9x
Ptprs
Fabp4
Cd36
Pck1
Pdk4
Cidec
Tfrc
Ucp3
Cyr61
Lrp2bp
gPdk4
Pdk4_eRNA+1
Pdk4_eRNA+2

Forward Sequence
GTGGACTATCCGGCCTA
GAA
CTGGACGGAGGAGAAC
TCAC
AGGCCTCATGATCACCA
TCT
CTCCTGGCCACCCAGAA
T
GTTGACCGCAGAGATGA
AGG
TTGCCCTCCTTCTACAAT
CC
CATCTTGCAGAGACCAT
TGC
TGATATTCACATTCCCA
CCG
CACTTTCCTTGTGGCAA
AGC
TCAGAAGCAGGAAGGG
AGTG
AGGCCTCCCAACATTCA
TTA
ATCATCTTTGGTGGCCG
TAG
ATTGTGCCATCTTCCTCC
AG
CAGTCCAGCTGGCAAAG
ATT
GTTCCTTTGCTGCCTATG
GA
TTTACAGTTGGGCTGGA
AGC
TTTCAAGTGCATTGTCT
GGG
TAACTATGCCGTGCACC
AAA
GGACAGAGGCCCAAAT
GTTA
AGAGTTCTCTGGGGGAA
AGG
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Reverse Sequence
GTGCACAATCAAACCAAAC
G
GGACAACCTGACTTCCTTGG
GGTCTCAGCAGTGCAAACA
G
GCTGTCAGAATGCACAGCTC
CCTGTAGCTCAGCCAAGTCC
ATTCGCCGTGGACTTCTTC
TTTGTTGGGTTCGCCATATT
ATCACCTGCCAACCTCTACG
AATGTGTGATGCCTTTGTGG
ATTGCACAAGGCACACAAA
G
GATCATAGCCATGGTCAGCA
CATGGCTGCTCCTACAAACA
ATCATGGCTCACAGCTTGG
GTCCAGTGTGGGAACAGGT
C
TACCCAACCTTGGCTAGACG
CACCGCTCTGAAAGGGATCT
TATTATGATGGGCTGGGGAC
AAAGGCTCAAGGGGAAGAG
A
CTTGTGAAGCAGACCCAGTG
CCACTTGGGCAACAGAATTT

Pdk4_eRNA-1
gFabp4
Fabp4_eRNA217
Fabp4_eRNA192
gAngptl4
ePparg_up213
Arbp

CTATGGCTGGCACTGGA
GTT
ATCGGGAATTTCAGCAT
GAC
AACATCCGAATCAACCG
TTC
TGAGTCCCCCACTTGCT
TTA
ACCCAAGGCCAGAATCT
CTT
AGAGCTCTTACCCAGCA
GAGA
CCGATCTGCAGACACAC
ACT
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TCCCCTCCTTTTGACTCTCA
AATGTGTGATGCCTTTGTGG
GGTGGGACAAACAAAATTC
C
CACCCTGTAAGGCTGGTGAT
TTGCTGTCATCTGGCAACTC
GCACACCAGGCAAGTGCTA
T
ACCCTGAAGTGCTCGACATC

CHAPTER 5: Discussion and future directions
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5.1 Summary and discussion
In the studies summarized above, we have further elucidated the effects of PPAR
ligands on adipocyte transcription. In Chapter 2, we examined the immediate and direct
effects of rosi on gene transcription using GRO-seq. We found thousands of rapidly
regulated genes, 2/3 of which were down-regulated by rosi. These regulated nascent
transcripts are highly correlated with changes in steady-state mRNA levels as identified
by microarray, but with a temporal delay. Interestingly, the correlation between nascent
transcript and steady-state mRNA level waned at later microarray time points, after 12 or
24h, suggesting that steady-state levels likely have other contributing factors besides
direct transcriptional changes, as discussed in Section 5.2a below.

In Chapter 3, we used GRO-seq to identify regulated eRNAs. We could not demonstrate
any role for these eRNAs in promoting transcription of the target gene, despite several
recent studies that suggest this function (Lam et al. 2013; Li et al. 2013; Melo et al. 2013;
Mousavi et al. 2013). We did, however, use these regulated eRNAs to determine
functional enhancers. By focusing exclusively on the functional enhancers, we were able
to identify changes in coactivator occupancy that would not have been identifiable by
determining all TF binding sites genome-wide. We found that enhancers containing an
up-regulated eRNA are driven by PPAR, while enhancers with down-regulated eRNAs
are depleted of PPAR but are enriched for other TFs, including members of the C/EBP
and AP-1 families. Additionally, in response to rosi treatment the coactivators MED1,
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CBP, and p300 are recruited to sites of up-regulated eRNAs and lost from sites with
down-regulated eRNAs. These findings suggest a mechanism wherein rosi treatment
causes increased recruitment of coactivators to PPAR sites and away from sites
containing other TFs, leading to transcriptional repression at these sites and at their target
genes. This suggests that, in principle, any TF driving transcription at an enhancer
lacking PPAR would be susceptible to the loss of coactivators and subsequent
transcriptional repression. Indeed, this may explain why the down-regulated enhancers
are enriched for binding of multiple factors, including C/EBP, C/EBP, FOSL2, ATF2,
and JUND.

These studies shed light onto the mechanisms by which rosi affects adipocyte
transcription, especially the ways in which it leads to transcriptional repression, a
phenomenon of which we previously had very little understanding. In addition, we
believe that the approach we took in these studies – using regulated eRNAs to identify
functional enhancers, and focusing on these sites to identify enriched motifs, critical TFs,
and changes in coactivators – could be applied to many other questions of transcriptional
regulation. In other systems in which a signal or cue causes transcriptional changes
through unknown mechanisms, this method can be taken to discover key enhancers and
TFs that are driving the changes. For example, the Lazar lab recently used a similar
approach to identify enhancers and TFs that are important for circadian regulation of
transcription in the liver (Fang et al. 2014).
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In Chapter 4, we sought to determine whether differential gene regulation by MRL-24
was driven by differential use of enhancers, and whether the mechanism of its
transcriptional regulation was distinct from that of rosi. However, we found that in our
adipocyte model MRL-24 did not regulate a unique subset of gene targets, but rather
functioned similarly to a partial PPAR agonist. This difference in results is likely
attributable to differences in cell culture models, and studying it further in vivo may
clarify its effects.

5.2 Future directions
5.2a Identifying secondary targets of rosi
In Chapter 2, we determined that although nascent gene transcription is highly correlated
with steady-state mRNA levels after 6 to 12 hours of rosi treatment, this correlation is
weaker when nascent transcription from GRO-seq is compared to later microarray time
points. This suggests that steady-state mRNA levels that are reached after 24h of rosi
treatment are determined not only by direct transcriptional changes due immediately to
rosi treatment, but by other factors as well, which may include secondary transcriptional
changes and non-transcriptional regulation such as changes in mRNA degradation rates.
Though we gained many mechanistic insights by examining early direct changes due to
rosi treatment, studying later, secondary effects is equally important because these are the
changes that ultimately contribute to the function and phenotype of rosi treatment. Thus,
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determining which genes are controlled by rosi at later, steady-state time points and the
mechanisms of this regulation are important future directions.

An important follow-up experiment would be to perform GRO-seq on adipocytes treated
with rosi for a longer period of time, such as 24 or 36 hours. First of all, this would
identify genes that are transcribed as a downstream response to rosi treatment, and these
would be expected to correlate more strongly with later time points from the microarray
experiment. It would also distinguish genes that are secondary transcriptional targets
from those that are regulated in a non-transcriptional manner, such as through
degradation rates. Lastly, analysis of eRNAs at later time points of rosi treatment would
identify functional enhancers that are regulating these downstream gene targets. Similar
to the approach we took in Chapter 3, motif analysis of the enhancers that are regulated at
later time points may help identify TFs that are induced by rosi treatment and control
downstream gene transcription. If such a TF is identified that putatively controls longterm steady-state response to rosi, its role could be verified by ablating its expression and
testing whether this blocks secondary responses to rosi treatment. It would also be
interesting to explore how these downstream regulated enhancers control both
transcriptional activation as well as repression, and whether repression of secondary gene
targets is through an effect similar to coactivator redistribution as shown in Chapter 3, or
through a different mechanism.

93

5.2b Connecting coactivator redistribution to transcriptional regulation
In Chapter 3 we demonstrated that rosi treatment causes a redistribution of coactivators
(including MED1, CBP, and p300) to enhancers containing PPAR and away from
enhancers containing other TFs. We observed no change in the occupancy of the
corepressor NCoR or in levels of the histone mark H3K27ac at those sites where
coactivator levels changed. A clear next question is how exactly changes in coactivator
occupancy are leading to changes in transcription.

Coactivators are known to promote transcription mainly through a few different
functions: modifying chromatin, recruiting components of the transcriptional machinery,
and promoting long-range looping between the enhancer and promoter (Carlsten et al.
2013; Grunberg and Hahn 2013). When coactivators are redistributed in response to rosi,
one of these mechanisms – or a novel one – must be at play to regulate subsequent
changes in transcription. The coactivators CBP and p300, which we showed were
redistributed, are known to function as histone acetyltransferases (Schiltz et al. 1999),
suggesting a role for histone acetylation in connecting coactivator occupancy to
transcription. However, our finding that H3K27ac levels do not change at a few
enhancers where eRNAs are regulated suggests that chromatin modification may not be
the primary mechanism of transcriptional regulation, although this is far from conclusive.
We only tested levels of this chromatin mark at a few sites, so making genome-wide
conclusions could be premature. We also only tested one time point – after 1h of rosi
treatment – but this mark may be changing later, or it may in fact be changing even
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earlier (since we see eRNA changes as soon as after 10 minutes of rosi), then normalizing
back to basal levels. Testing other chromatin marks, as well as at more enhancer sites and
at different time points may elucidate a role for chromatin modifications in the link
between coactivator occupancy and transcriptional changes.

The other mechanisms, including differential recruitment of transcriptional machinery
should be tested as well. For example, the Mediator complex has been shown to interact
directly with Pol II, and is required for transcription (Soutourina et al. 2011). CBP and
p300 interact with the basal transcription factors TATA-binding protein (TBP) and TFIIB
(Yuan et al. 1996).

This suggests the mechanism that upon redistribution of these

coactivators, they in turn differentially bind and recruit elements of the basal
transcriptional machinery, leading to changes in transcription. Binding of Pol II, TBP,
TFIIB, and other factors could be tested by ChIP. However, most of the regulated
functional enhancers we identified were distal from genes, tens or even hundreds of
kilobases away from the TSS. Therefore, changes in recruitment of the transcriptional
machinery to these sites would explain regulation of eRNA transcription, but would not
explain changes in gene transcription without additional information about long-range
chromatin interactions between enhancers and gene promoters.

Thus, studying chromatin loops between enhancers and promoters, and how they may
change upon rosi treatment, would be an important component of further understanding
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this transcriptional regulation. The first goal would be to determine which enhancers loop
to which gene promoters, to identify each enhancer’s target gene. This would be a much
more conclusive way of determining enhancer-gene pairs, compared to relying on using
the nearest regulated gene for each enhancer, as we had to do in Chapter 3 due to the lack
of chromatin looping data. The existence and regulation of chromatin loops could be
explored at a few select enhancers and promoters by chromatin conformation capture
(3C) or circular chromosome conformation capture (4C), although ideally all chromatin
loops in the genome would be identified by Hi-C (Dekker et al. 2013). Another important
question would be whether rosi modifies gene transcription levels by regulating the
strength of the chromatin loops, or whether the loops stay the same but recruitment of
additional transcription factors is what drives the transcriptional changes. Since the
Mediator complex has been implicated in the formation of chromatin loops (Carlsten et
al. 2013), and we demonstrated a rosi-dependent redistribution of the Mediator subunit
MED1 at regulated enhancers, we would hypothesize that rosi treatment may indeed
strengthen enhancer-promoter loops at up-regulated sites, and weaken them at downregulated sites. These studies would mechanistically link changes in coactivator binding
to changes in eRNA and gene transcription.

5.2c Determinants of functional enhancers
In Chapter 3, we identified 2,251 distal enhancers with regulated eRNAs; these are the
enhancers we termed “functional.” However, they make up a relatively small fraction of
all putative enhancers as defined by TF binding sites. For example, we had 14,604
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PPAR binding sites in our data set, in which sites were called after pooling reads from
two published cistromes (Nielsen et al. 2008; Schmidt et al. 2011), and similar numbers
for other TFs bound in adipocytes, including the members of the C/EBP and AP-1
families described in Chapter 3. Only a small number of these sites produce eRNAs. This
can be explained in part by the fact that we only called eRNAs at intergenic sites for
technical reasons, while TFs bind at many intronic sites. Nevertheless, even when
considering just intergenic TF binding sites, those with eRNAs make up only about half
of the total in the case of PPAR (Step et al. 2014).

Thus, an important follow-up question is: what distinguishes the relatively small number
of “functional” enhancers from the rest of the thousands of TF binding sites? What
feature determines whether a putative enhancer produces an eRNA? We know that part of
the answer involves strength of binding of the TF: PPAR sites with eRNAs tend to be
strong sites than those without eRNAs (Step et al. 2014). However, this is unlikely to be
the whole explanation, since the trend is strong but not overwhelming. Perhaps there is a
factor that is able to bind to certain TF binding sites but not others, and is able to act
together with the TF to recruit coactivators and other factors to drive eRNA transcription.
To investigate this, all putative enhancers could be divided into two groups: those that
produce an eRNA and those that do not. Then, the presence of an eRNA can be correlated
with binding of other known TFs in adipocytes, to determine whether colocalization of
another factor with PPAR is necessary for the production of an eRNA at an enhancer.
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Motif searches could also be performed around enhancers that do or do not contain
eRNAs to determine if response elements for a given TF are enriched around one group
or the other. Identifying what distinguishes functional enhancers from other TF binding
sites would be important not only in understanding rosi-mediated regulation of
adipocytes, but also transcription in any other cell type in response to a stimulus.

5.2d Other compounds that differentially regulate PPAR
As discussed in Chapter 1, TZDs are able to potently improve insulin sensitivity and
lower glucose levels, but have been linked to multiple safety issues. Because of these
effects, there has been much interest in the development of selective PPAR modulators,
or SPPARMs, small molecules that would agonize the TF in a way that would lead to
differential gene expression. The goal of these SPPARMs would be to retain the insulinsensitizing effects of TZDs but without the unwanted side effects of full receptor
activation (Higgins and Depaoli 2010).

In Chapter 4, we studied MRL-24, which had been described as a ligand of PPAR that
regulates a distinct subset of target genes yet still functions as an effective insulin
sensitizer in vivo. Instead, we found that in our cell culture model of adipocytes, MRL-24
did not have any unique gene targets, but rather functioned by regulating most of the
same genes as rosi but to a lesser degree. Nevertheless, other SPPARMs are still being
investigated, including a compound called INT131. A clinical study recently showed that
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INT131 demonstrated reductions in HbA1c (glycated hemoglobin, a time-averaged
measure of blood glucose levels) comparable to pioglitazone, with less fluid
accumulation and weight gain (DePaoli et al. 2014). This exciting result suggests that
PPAR may still be a relevant target for new drug development for diabetes treatment.
Biochemical and cell-based studies suggest that INT131 may be acting as a SPPARM:
treatment of 3T3-L1 preadipocytes with this drug caused very little adipogenesis or lipid
accumulation, whereas rosi treatment caused full differentiation. It also induced most
adipogenic genes to a much smaller extent than did rosi. Finally, an in vitro assay that
measures the strength of interaction between the PPAR LBD and coactivators
demonstrated that while rosi causes a large increase in recruitment of coactivators such as
SRC2, CBP, and p300, INT131 had a much smaller effect (Motani et al. 2009).

However, it should be noted that all of these effects are equally consistent with INT131
acting as a partial agonist. Genome-wide transcriptional studies of its effects would be
better able to discern between a partial agonist and a SPPARM. GRO-seq should be
performed on adipocytes treated briefly with INT131, and its direct transcriptional effects
compared to that of rosi. If it is truly a SPPARM, a distinct group of immediate gene
targets should be differentially regulated by the two compounds, whereas if it is a partial
agonist, most of the same genes would be regulated but to different degrees. Additionally,
it would be interesting to analyze eRNAs in this GRO-seq experiment to determine
whether INT131 is regulating the same group of functional enhancers as rosi, or a distinct
subset. This would also contribute to the understanding of INT131 as either a SPPARM
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or a partial agonist. Finally, measuring changes in coactivator occupancy upon INT131
treatment would demonstrate whether it acts similarly to rosi, by redistributing
coactivator binding genome-wide to regulate transcription both positively and negatively.
It would also be crucial to investigate whether any differences between the mechanisms
of action of the two compounds are related to the differences in their toxicity profiles.
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